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 “Not only life might thus be kept up both in the head and in 
any other portion separated from the body of an animal, but it 
might also be re-produced after its entire extinction. It might 
be restored likewise to the whole body, and thereby a 
complete resurrection be performed in the full extent of the 
word.”  
 
JJC Le Gallois, Experiences in the Principle of Life, 1813. 
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Foreword 
More than thirty years ago, when I just had started the training in extracorporeal life 
support technology the disc oxygenators where still in use. The most dramatic and 
somewhere devastating effect of these decades of clinical experience with heart-lung 
machine is described best by the words of Dr. Denton Cooley “At that time I developed 
an impression, which has lasted through almost my whole career, that the important 
thing in cardiopulmonary bypass was to get the patient the hell off the pump as soon 
as possible.” This idea of innate evil of cardiopulmonary bypass (extracorporeal life 
support) persists even now, after 10-15 years of development of new technologies. 
However, nowadays extracorporeal life support possessed numerous tools and 
methods. These allow specialists to choose the best possible individualized handling of 
each patient. But, on other hand such widening of possibilities requires not only deep 
theoretical knowledge, but also continuous analysis and systematization of practical 
experience.  
 The view at the possible gemmating of extracorporeal technology as an 
independent interdisciplinary science is described in the editorial ‘A glance to the 
future’ and presented as introduction of this thesis. 
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CHAPTER 1  
Introduction ‘A glance to the future’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YM Ganushchak, PW Weerwind and JG Maessen 
Published as an Editorial in: Perfusion 2012; 27:95-96. 
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The editorial ‘Why look backwards?’ by Mark Kurusz [1] can be seen as a landmark that 
summarizes the human dimension of more than a half-century history of 
extracorporeal life support. Extracorporeal life support has made a quantum leap 
during the last two decades. Development of safer extracorporeal technology 
stimulated the spread of cardiac surgical procedures throughout the world, as well as 
the development of new surgical methods, widened the types of treated pathology, 
and extended the age limits of patients treated. One of the powerful stimuli in the 
explosive innovation in extracorporeal technology was the re-introduction of ‘off-
pump’ coronary bypass surgery in the early 1990s. Promising results of the first two 
large series on ‘off-pump’ coronary bypass surgery, economic reasons [2,3], and the 
interest in minimally invasive coronary surgery through mini-thoracotomy approaches 
as well, encouraged the adoption of this technique throughout the world [4]. The 
decreasing demand for cardiopulmonary bypass procedures with the wide use of ‘off-
pump’ methods acted as a stimulus for inventions such as new blood-surface coatings, 
resulting in more efficient and biocompatible oxygenators and systems. Blood-saving 
methods and techniques for preventing haemodilution were developed and found 
recognition worldwide during this period as well. Moreover, enhanced 
biocompatibility and robust extracorporeal equipment (re-)opened exceptionally wide 
horizons for extracorporeal life support in intensive care therapy, resuscitation, 
oncology, organ preservation, and invasive cardiology, in addition to traditional 
applications in cardiac and vascular surgery. 
 Despite tremendous progress in equipment and the expanding areas where the 
methods of extracorporeal life support are applicable, the structure of the profession, 
as well as the theory behind extracorporeal life support, is now just making the first 
uncertain steps from the primary seas of protoscience to the shore sands of 
established and well-respected science. Science as a systematic enterprise that builds 
and organizes knowledge in the form of testable explanations and predictions 
definitely exists in extracorporeal life support methodology. However, still, even the 
everyday routine cardiopulmonary bypass procedure for cardiac surgery demands not 
only broad knowledge, but also ‘hands-on’ experience, fast deductive reasoning and, in 
part, something indefinable. Patient survival is often determined in the minutes it 
takes for cellular death to occur due to ischemia. So, it is a one shot deal, without any 
chance for replay. In other words, a perfusionist must provide mastery to even routine 
cardiopulmonary bypass to bring about a satisfactory outcome. A gigantic divergence 
between the newest highly sophisticated equipment, fast expansion in new fields of 
activities, and limited understanding of involved processes attracts and demands more 
and more attention today [5,6].  
 The sometimes ‘lagging behind’ in perfusion technology can be related to the 
relatively late germination of technology and sometimes feigned absence of a niche in 
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an academic level of the medical science structure. However, the interdisciplinary 
nature of required knowledge and, inherent with this, obstacles in formation and 
development of science are most important. Perfusion technology or, as more 
commonly used by most authors and clinicians, cardiovascular perfusion, can be 
defined as a profession that combines technical expertise and medical knowledge [5]. 
Despite the apparent simplicity of this definition, it demonstrates the necessity of 
assimilating knowledge across a wide range of scientific specialties, encompassing, 
among others, biology, physiology, pathophysiology, biochemistry, physics, 
bioengineering, and medical science. The interdisciplinary nature of this emerging 
profession is reflected in a wide diversity of required backgrounds of new recruits. The 
task of the new generation is not simpler than the task of the pioneers. This task is to 
melt diverse ingots of knowledge from a wide range of academic fields into a single 
discipline. 
 It is absolutely right that the ‘war stories’ of the first generation become historical 
footnotes with development of new technologies and extensive accumulation and 
sharing of experience and knowledge. However, what we cannot forget, put into 
footnotes, are the spirit, good will, and dedication of the pioneers. We must preserve 
and foster their devotion to the coming generations. 
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Outline of this thesis 
This dissertation presents a collection of studies that illustrates a first effort of 
“consilience” of several branches of physical sciences as well as life sciences. The 
following chapters outline the boundaries, present examples of investigation methods, 
and mark the frontier areas where the expertise of the clinical perfusionist is required. 
 
Chapter 2 a retrospective study on neurological complications after coronary artery 
bypass grafting is used as an example of a possible way to distinguish extracorporeal 
life support related factors (or combinations of factors), which influenced the outcome 
of surgery. The use of clinical endpoints in investigation of extracorporeal life support 
was demonstrated. Additionally, a method for the analysis of the required enormous 
amount of data was presented. 
 
Chapter 3 is dedicated to the two fundamental aspects of cardiopulmonary bypass. 
First, the relation between oxygen consumption and oxygen delivery during 
cardiopulmonary bypass was described. These parameters and their relation where 
used as a complex surrogate end point of a prospective clinical study. Second, the 
‘individual reference values’ of these parameters for an extracorporeal life support 
procedure were defined. This latter aspect is of great importance, both for practical 
and for theoretical development of the profession. 
 
Chapter 4 focuses on the keystone of extracorporeal life support, i.e. the 
understanding that during cardiopulmonary bypass ‘patient-heart-lung machine’ is a 
one-piece system. Another very important message of this chapter is the necessity to 
use clear quantitative terms in description of this system. The effect of oxygenator 
mechanical characteristics on energy transfer during clinical cardiopulmonary bypass 
demonstrates how individual components of the cardiopulmonary bypass system 
affect created flow and energy.  
 
Chapter 5 demonstrates the necessity of technical knowledge and understanding of 
processes involved in everyday practice, focusing on centrifugal blood pumps. 
 
O U T L I N E  O F  T H I S  T H E S I S  
 18 
Chapter 6 deals with the development of new, low volume systems for extracorporeal 
life support during cardiac surgery procedures, particularly the safety of these so-
called mini-systems. The use of combination of clinical findings and experimental as 
expansion and explanation of study results was demonstrated in this study.  
 
Chapter 7 is the general discussion where the main subject of extracorporeal life 
technology as an interdisciplinary science was defined as an integral heart-lung 
machine - patient system with unique, specific relations and reference values. 
Herewith optimal practice in management of extracorporeal life support is the careful, 
forthcoming balance between individual patient’s requirements and limitations. 
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CHAPTER 2 
Neurological complications after coronary 
artery bypass grafting related to the 
performance of cardiopulmonary bypass 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YM Ganushchak, EJ Fransen, C Visser, DS de Jong, and JG Maessen 
Published in Chest 2004; 1256:2196-2205. 
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Abstract 
 Study objectives: Neurologic disorders belong among the most serious 
complications of cardiac surgery. We tested the hypothesis that combinations of 
hemodynamic events from apparently normal cardiopulmonary bypass (CPB) 
procedures are related to the development of postoperative neurologic complications 
and affect the impact of common clinical risk factors. 
 Design: Retrospective study. 
 Setting: Cardiothoracic surgery department in a university hospital. 
 Methods and patients: A multivariate statistical procedure (i.e., cluster analysis) 
was applied to a data set of automatically recorded perfusions from 1,395 patients 
who had undergone coronary artery bypass grafting. One-way analysis of variance was 
used to select five parameters with the strongest significant correlation to 
postoperative neurologic complications for further cluster analysis. The dependencies 
in the clusters were tested against common clinical risk factors. To our knowledge, this 
is the first study of its kind. 
 Results: The following five parameters emerged for cluster analysis: mean arterial 
pressure (MAP); dispersion of MAP; dispersion of systemic vascular resistance; 
dispersion of arterial pulse pressure; and the maximum value of mixed venous 
saturation. Using these parameters, we found four clusters that were significantly 
different by CPB performance (first cluster, 389 patients; second cluster, 431 patients; 
third cluster; and fourth cluster, 229 patients). The frequency of postoperative 
neurologic complications was 0.3% in the first cluster and increased to 3.9% in the 
fourth cluster. Importantly, the impact of common clinical risk factors for 
postoperative neurologic complications was affected by the performance of the CPB 
procedure. For example, the frequency of neurologic complications among patients 
with cerebrovascular disease in their medical history was 22% in the fourth cluster, 
whereas it was zero in the second cluster.  
 Conclusions: This study shows that apparently normal CPB procedures affect the 
impact of common clinical risk factors on postoperative neurologic complications. 
Patients who underwent CPB procedures with large fluctuations in hemodynamic 
parameters particularly showed an increased risk for the development of 
postoperative neurologic complications. 
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Introduction 
CNS disorders after coronary artery bypass grafting (CABG) significantly increase 
perioperative mortality and hospitalization time, and can lead to a decrease in the 
patient’s quality of life. The reported rate of major postoperative neurologic 
complications, such as stroke, varies from 0.8 to 6% [1-4]. Mechanisms causing these 
complications are not well understood. Previous studies have focused primarily on the 
separate identification of demographic and medical risk factors. A number of risk 
factors thus have been identified (e.g., age, female sex, cranio-cervical and aortic 
atherosclerosis, previous cerebral stroke, hypertension, duration of the operation and 
cardiopulmonary bypass (CPB), use of the intra-aortic balloon pump, and 
postoperative cardiac arrhythmias) [2-7]. As to the intraoperative factors, neurologic 
complications after cardiac operations have been attributed mainly to the effects of 
CPB [8]. Reported potential mechanisms are the microembolization and 
macroembolization of gas, particle matter, and inadequate cerebral perfusion pressure 
or flow. However, studies on the impact of conventional, uncomplicated CPB are rare 
and usually are performed on small, selected groups of patients. Furthermore, the 
multifactorial nature of neurologic dysfunction after CPB makes the results of such 
investigations controversial. 
 We undertook this retrospective study to deter mine which combination of 
preoperative and intra- operative risk factors, including the characteristics of CPB, 
might predispose CABG patients to neurologic complications following surgery. The 
use of a fully automated system of perfusion record keeping provided continuous data 
and eliminated the possible bias that is inherent to manual record entry. Groups of 
patients with similar perfusion characteristics were separated by means of cluster 
analysis to study the interaction between the characteristics of CPB and common 
clinical risk factors. To our knowledge, this is the first study of its kind. 
Materials and Methods 
Patients 
Retrospectively, 1,408 isolated CABG operations that had been carried out between 
May 1996 and January 1999 in the University Hospital Maastricht were reviewed. 
Patients with incomplete intraoperative or postoperative data were excluded from 
study. 
C H A P T E R  2  
 22 
Intraoperative Patient Management  
The conduct of anesthesia and CPB was standardized by hospital practice. Anesthesia 
was induced with midazolam (0.06 to 0.08 mg/kg), sufentanil (1 to 1.5 µg/kg), and 
pavulon (0.1mg/kg), and was maintained with sufentanyl (0.5 to 1.25 µg/kg/h) and/or 
propofol infusion (3 to 6 mg/kg/h). The bypass circuit consisted of a hollow fiber 
oxygenator (Univox-IC; Bentley/ Baxter; Irvine, CA; or Capiox SX; Terumo Corporation; 
Tokyo, Japan), an arterial line filter (Pall Autovent-SV; Pall Biomedical Ltd; Portsmouth, 
UK), and a roller pump (Stöckert Instrumente GmbH; Munich, Germany). The circuit 
was primed with a mixture of colloidal intravenous infusion solution (Haemaccel; 
Beacon Pharmaceuticals; Tunbridge Wells, UK) (3.5%; 1,200 to 1,300 mL), mannitol 
(20% solution; 200 mL), human albumin (20%; 100 mL), NaHCO3 (8.4%; 50 mL), 
potassium chloride (20 mmol), and heparin (50 mg/1,000 mL colloidal intravenous 
infusion solution). CPB was carried out by means of pulsatile flow with a flow range of 
approximately 2.4 L/min/m2. Moderate hypothermia (i.e., temperature, 28°C to 32°C) 
was applied during the CPB. A modified St. Thomas solution was used to arrest the 
heart and to maintain it in an isoelectric state. After the release of the aortic clamp, a 
nitroglycerine infusion (0.5 µg/kg/min) was started. 
Data Collection 
All demographic and clinical data were stored in using a software program (Summit 
Medical Systems; Minneapolis, MN).  
 Postoperative neurologic complications were defined as follows: permanent or 
transient central neurologic deficit; mental disturbance marked by illusions, confusion, 
and cerebral excitement; and unresponsive coma for > 24 h. In all cases, patients with 
possible neurologic complications were investigated by a neurologist. This as well as 
other definitions for clinical parameters was derived from the terms of the Society of 
Thoracic Surgeons National Cardiac Surgery Database (Table 1).  
 In 1996, the department of Extra-Corporeal Circulation introduced a computer 
program (homemade) for the continuous registration of perfusion parameters. 
Routinely, every 6 s, 21 parameters of CPB are read and stored in a data file. For the 
present study, the following parameters were extracted from the perfusion database: 
mean arterial pressure (MAP); arterial pulse pressure (APpulse); blood flow index (BFI); 
systemic vascular resistance (SVR); arterial blood temperature; rectal temperature; 
PaO2; and mixed venous saturation (SvO2). Also the duration of full extracorporeal 
circulatory support (i.e., aortic cross-clamp period or full bypass) was included in the 
analysis. Continuous perfusion parameters from each single CPB procedure were 
included in the study as their mean, maximum, and minimum values during each single 
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procedure. As a degree of the scattering of data, we also included a variable that we 
called dispersion. Dispersion is a measure that points out how often and how far the 
values of the included parameters changed through the full period of CPB for each 
single procedure. Thus, continuous parameters in our study were presented by their 
four properties, as follows: mean; dispersion; maximum; and minimum. 
 
Table 1—Demographic and Clinical Variables* 
Variables Description
 
Age As discrete variables (i.e., < 57, 57-64, 65-70, and > 70 yrs.) 
Hypertension BP > 140/90 mmHg, a history of high BP, or the need for 
antihypertensive medications 
Carotid vascular disease A history of carotid disease (left and/or right) and/or prior 
carotid endarterectomy (left and/or right) 
Diabetes mellitus A history of diabetes, regardless of duration of disease, or need 
of insulin or oral hypoglycemic agents 
Overweight BMI > 25
Perioperative myocardial infarction As documented in cardiology consultation
Postoperative cardiac arrhythmia The presence of atrial or ventricular ectopy (i.e., ventricular or 
atrial fibrillation, AV block, or ventricular tachycardia) 
Postoperative neurologic complications Permanent or transient central neurological deficit; mental 
disturbance marked by illusions, confusion, and cerebral 
excitement; unresponsive coma > 24 h 
Postoperative renal failure Defined as a significant renal complication with a serum 
creatinine level of > 150 µmol/L 
Preoperative LVEF Divided into two groups: LVEF < 60% and VEF > 60% 
Previous cerebral incident defined as prior stroke or TIA  
Prior cardiac surgery A history of prior CABG or prior valve surgery
 
Perfusion parameters 
Cardioplegia mL/10 kg/min
Aortic cross-clamp time Discrete variables (8-36, 37-48, 49-63, and 64-180 min) 
Duration of CPB Discrete variables (19-59; 60-75; 76-99; and 100-293 min) 
*TIA = transient ischemic attack; LVEF = left ventricular ejection fraction; BMI = body mass index 
Data Analysis 
From the initial 1,408 cases, 13 patients were excluded from further analysis because 
of incomplete or missing data from the CPB. None of these excluded patients had 
severe postoperative neurologic complications. Subsequently, a set of data from 1,395 
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cases was analyzed within a multidimensional space of 32 variables in order to identify 
data-dependent groups of perfusion patterns. One-way analysis of variance was used 
to compare the values of perfusion variables between patients who developed 
postoperative neurologic complications and those in whom such complications did not 
occur (Fig 1). A cluster analysis was used to look for “subpopulations” of patients, with 
respect to a selection of perfusion variables that were clinically relevant for 
postoperative neurologic complications. The following two procedures for cluster 
analysis were used: a hierarchical cluster analysis; followed by a K-means cluster 
analysis. This was done to fully profit from the strength of both procedures. The K-
means cluster analysis is the ideal analysis for large patient groups, however, the 
algorithm requires one to specify the number of clusters. We wanted these tests to be 
as objective as possible. Therefore, we first performed a hierarchical cluster analysis in 
which the decision making on the number of clusters to be used is automated. The 
drawback of the hierarchical cluster analysis is the fact that it is not specifically 
designed for large patient groups. Therefore, we randomly selected (SPSS software; 
SPSS Inc. Chicago, IL) a group of 387 case patients (28% of the total population) for the 
hierarchical cluster analysis. Thus, the steps for the total clustering process were as 
follows. 
 The first step in the cluster analysis was the selection of variables to identify a 
likely set of variables to “carve” the patient population into subgroups (Fig 1). A 
preliminary analysis revealed that patients with and without complications in the early 
postoperative period had undergone perfusions that differed from each other on more 
than a dozen parameters. For the cluster procedure, we selected the most 
representative parameters from groups of closely correlated parameters (see “Results” 
section). As an exception to this rule, we included the properties of the MAP in the 
cluster procedure. This exception was based on the hypothesis that the MAP during 
CPB is of high clinical significance. Thus, five parameters (i.e., mean MAP, dispersion of 
MAP, dispersion of SVR, dispersion of APpulse, and maximum SvO2) were selected for 
the cluster analysis. From these parameters, standardized values (i.e., Z-score 
variables) also were generated. This Z-score transformation was done to prevent the 
variables with greater variability to dominate the clustering. 
 The second step was a hierarchical cluster analysis on a random subset of cases 
(387 cases, as described above), which was performed with the Z-score variables 
generated before (Fig 1). During the clustering process, clusters were formed by 
grouping patients into bigger and bigger clusters until all patients were members of a 
single cluster. The results of the hierarchical cluster analysis were summarized in a so-
called agglomeration schedule, which was presented as a table. This agglomeration 
schedule showed us the step-by-step clustering process and identified the clusters 
being combined at each stage. The results of this agglomeration schedule in a later 
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phase helped us to decide how many clusters should be included in our present study. 
The cluster method chosen was the between-groups linkage, and the dissimilarity 
measure we chose was the “squared Euclidean distance.” The latter allowed us to 
specify the distance or similarity measure to be used in clustering. 
In the third step, one of the variables in the agglomeration schedule, the coefficients, 
were used to select a four-cluster solution for further analysis. Then, a K-means cluster 
analysis based on the Z-scores of the five selected parameters was used to cluster all 
cases [9]. 
 
 
C H A P T E R  2  
 26 
Figure 1.The flow chart of statistical analyses. 
 
In order to study the interactions of patient age, duration of CPB, and development of 
neurologic complications, these continuous numeric data were converted to four 
discrete categories (Table 1) using the data transpose option of the software package 
(i.e., SPSS; SPSS Inc.). Analyses of the qualitative variables throughout the study were 
made using the χ2 test or extensions of the two-tailed Fisher exact test. One-way 
analysis of variance was used to compare the mean values of the quantitative variables 
N E U R O L O G I C A L  C O M P L I C A T I O N S  A F T E R  C A R D I O P U L M O N A R Y  B Y P A S S  
 27 
in clusters. The multiple comparison Tukey honestly significant difference test or the 
Tamhane T2 test was used to find which means were different in the clusters. Data 
analyses were per- formed using a statistical software package (SPSS, version 9.01; 
SPSS/PC+; Chicago, IL). 
Results 
Among the 1,395 patients enrolled in our final analysis, 27 (1.9%) had severe 
neurologic complications in the postoperative period. Demographic and clinical 
characteristics of all patients are shown in Table 2. A direct comparison of both patient 
groups points out that patients with postoperative neurologic complications were 
older, had previously experienced a cerebral stroke more often, had undergone more 
distal anastomoses, and had longer CPB and cross-clamp times. Postoperatively, the 
development of neurologic complications was associated with a number of other 
postoperative complications included in our study. Postoperatively, the majority of 
patients with a neurologic complication had this in combination with at least one other 
postoperative complication included in the analyses (22 of 27 patients; 81.5%). The 
most common complication to coincide with a neurologic complication was cardiac 
arrhythmia (21 of 27 patients; 77.8%).  
 CPB parameters in patients with or without post-operative neurologic 
complications are presented in Table 3. For the majority of parameters included in the 
present study, dispersion was significantly higher in patients with postoperative 
neurologic complications. 
 The separation of patients into four clusters is shown in Figure 2. Final cluster 
centers and related parameters are shown in Table 4. Clusters differed by all studied 
parameters, except for the maximum value of the arterial blood temperature. The first 
cluster united patients with a relatively “warm,” stable full bypass period, as shown by 
the low dispersion values for all parameters. On the contrary, the fourth cluster united 
CPB procedures with high alterations, especially of the hemodynamic parameters. 
Table 4 shows that CPB procedures in the fourth cluster had the highest dispersion of 
MAP  (mean ± SD) MAP dispersion, 13.7 ± 3.2 mmHg). In the fourth cluster, the MAP 
during CPB varied from 38 ± 8 to 97 ± 12 mm Hg. In other words, the MAP during this 
type of CPB procedure varied by almost 60 mmHg. The same tendency was found for 
the BFI. The mean dispersion of blood flow during CPB in cluster 4 was 0.2 ± 0.1 
L/min/m2 (p < 0.001 compared to any other cluster). The mean value of the BFI in CPB 
procedures from the cluster 4 was significantly lower than those in CPB procedures 
from cluster 1 (p < 0.001), but they did not differ from those in CPB procedures 
included in the clusters 2 and 3. The lower BFI in these clusters could be related to a 
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lower rectal temperature during CPB. A relatively high MAP in combination with low 
values of blood flow arbitrated that clusters 3 and 4 had the highest mean values of 
SVR during full bypass (1,440 ± 192 and 1,455 ± 266 dyne∙s∙cm-5, respectively). The 
fourth cluster had the highest values of SVR with an average maximum value up to 3,093 
± 1,860 dyne∙s∙cm-5 (p < 0.001 compared to any other cluster). The clusters were also 
different in terms of demographic, clinical, and intraoperative characteristics, as shown 
in Table 5. 
 
 
Table 2—Demographic, clinical, and operative characteristics of patient groups* 
Variable Postoperative Neurologic Complications p Value  
Yes (n = 27) No (n = 1,368) 
Age, yr 69 ± 8 63 ± 9   < 0.01 
BSA, m2 1.85 ± .2 1.92 ± .2 0.04 
Obesity (BMI > 25)  66.7 69.5 0.83 
Female sex 40.7 25.5 0.08 
Hypertension 44.4 29.8 0.14 
Previous cerebral incident 29.6 6.4  < 0.001 
Carotid disease 11.1 3 0.05 
Diabetes mellitus 11.8 7.4 0.57 
Prior cardiac surgery 7.4 7.2   > 0.99 
Preoperative LVEF < 60 25.9 17.4 0.3 
IABP before operation 11.1 5.3 0.17 
CPB duration, min 103 ±43 82 ± 3 0.01 
ACC duration, min 64 ± 6 52 ±22 0.03 
Cardioplegia, mL/10 kg/min 2.9 ± .3 2.6 ± .0 0.79 
Proximal anastomoses 1.3 ± .5 1.1 ± .4   < 0.01 
Distal anastomoses 4.2 ± .8 3.7 ±1.1 0.01 
IABP after operation 11.1 4.3 0.12 
Postoperative cardiac arrhythmias 77.8 23.1   < 0.001 
Postoperative myocardial infarction 14.8 3.6 0.02 
Postoperative renal failure 25.9 5.3   < 0.01 
*Values given as mean ± SD or %, unless otherwise indicated. ACC = aortic cross-clamping; BSA = body 
surface area; IABP = intraaortic balloon pump. See Table 1 for other abbreviations not used in the text. 
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Table 3—Perfusion parameters in both patient groups* 
Variable Parameter 
Properties 
Postoperative Neurologic Complications p Value  
 Yes (n = 27) No (n = 1,368)  
BFI, L/min/m2 Mean 2.4 ± 0.2 2.3 ± 0.2 0.13 
Dispersion 0.15 ± 0.08 0.12 ± 0.09 0.14 
Maximum 2.7 ± 0.2 2.6 ± 0.2 0.02 
Minimum 1.3 ± 0.7 1.5 ± 0.7 0.13 
MAP, mmHg Mean 66.6 ± 13.4 63.2 ± 10.6 0.11 
Dispersion  9.9 ± 3.9 8.5 ± 3.6 0.04 
Maximum 87.8 ± 17.6 82.8 ± 14.7 0.08 
Minimum 41.3 ± 11.6 42.9 ± 10.3 0.41 
APpulse, mmHg Mean 24.9 ± 6.8 22.2 ± 7.7 0.07 
Dispersion 5.3 ± 2.2 3.9 ± 2.2       < 0.001 
Maximum 35.4 ± 8.8 30.7 ± 11.3 0.03 
Minimum 8.74 ± 5.9  8.6 ± 5.8 0.87 
SVR, dyne∙s∙cm-5 Mean 1343 ± 246 1258 ± 254 0.08 
Dispersion 251 ± 128 194 ± 107        < 0.01 
Maximum 2754 ± 1720 2152 ± 1209 0.01 
Minimum 780 ± 168  815 ± 216 0.4 
Temperature, °C     
Arterial Mean 31.0 ± 2.2 31.8 ± 2.3 0.08 
Dispersion 2.5 ± 1.2 2.1 ± 1.1 0.07 
Maximum 36.2 ± 1.9 36.3 ± 1.6 0.76 
Minimum 26.6 ± 4.1 27.7 ± 3.8 0.16 
Rectal Mean 32.0 ± 2.0 32.8 ± 1.9 0.04 
Dispersion 1.1 ± 0.5 0.8 ± 0.5 0.02 
Maximum 34.7 ± 2.5 34.9 ± 1.4 0.45 
Minimum 30.7 ± 2.5 31.7 ± 2.5 < 0.01 
PaO2, kPa Mean 17 ± 5 16 ± 5 0.32 
Dispersion 2.8 ± 1.5 2.7 ± 1.6 0.72 
Maximum  28 ± 9 26 ± 10 0.33 
Minimum 11 ± 1 10 ± 1 0.29 
SvO2, % Mean 79.6 ± 5.9 76.1 ± .4 < 0.01 
Dispersion 4.2 ± 1.8 3.5 ± 1.6 0.02 
Maximum 86.6 ± 5.0 82.5 ± 6.0 < 0.001 
Minimum 66.3 ± 9.3 65.3 ± 7.8  0.51 
*Values given as mean ± SD, unless otherwise indicated. 
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Figure 2. The graphical presentation of 4 clusters in three dimensional 
space. Red dots mark cluster 1, green dots mark cluster 2, yellow dots 
mark cluster 3, and blue dots mark cluster 4. 
 
Table 5 shows that the fourth cluster contains the oldest patients, the highest 
percentage of female patients, and patients with cerebrovascular disease in their 
medical histories. The cluster means of CPB duration, cross-clamp time, and number of 
distal anastomoses were statistically different among clusters (p < 0.001). Post hoc 
testing showed that the mean CPB duration in the second and third clusters and in the 
third and fourth clusters were equal (Table 5). Also, although a significant difference 
was found for the aortic cross-clamping times between clusters, the aortic cross clamp 
times in clusters 3 and 4 were identical. The mean number of distal anastomoses was 
significantly lower in the first cluster compared to all other clusters (p < 0.05) and was 
identical for clusters 2 to 4. The frequency of postoperative neurologic complications 
was the lowest in the first cluster (0.3%) and increased up to 3.9% in the fourth cluster 
(p < 0.01) (Table 5). From the 389 patients in the first cluster, only 1 patient (0.3%) had 
a postoperative neurologic disorder, which was experienced in combination with 
cardiac arrhythmias and renal failure. In the first cluster, 12 patients (3.1%) had a 
cerebral incident in their medical history. Remarkably, none of them developed 
neurologic complications in the postoperative period. The frequency of postoperative 
neurologic complications in the second cluster was 2.3% (10 patients), and the 
occurrence of this was associated with the occurrence of postoperative cardiac 
arrhythmias (p < 0.001). We did not find any association between the development of 
neurologic complications and any other demographic or clinical characteristic in this 
cluster. In the second cluster, 35% of all patients with cerebrovascular disease in their 
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medical history were included. None of these patients experienced a postoperative 
neurologic complication. Also, none of the 16 patients with carotid disease who were 
included in this cluster experienced a postoperative neurologic complication. In the 
third cluster, the frequency of postoperative neurologic complications was 2.0%. 
Cluster 3 contained 22 patients with a medical history of cerebral disease. Two of 
these patients (9.1%) developed neurologic complications postoperatively, but this 
association was not significant. However, the occurrence of postoperative neurologic 
complications in patients of the third cluster was associated with carotid disease and 
postoperative renal failure (p < 0.01 and p < 0.05, respectively). In the fourth cluster, 
the development of postoperative neurologic complications was associated with the 
occurrence of a perioperative myocardial infarction and postoperative cardiac 
arrhythmias (p < 0.01 and p < 0.001, respectively). From nine patients in the fourth 
cluster who experienced postoperative neurologic complications, eight patients 
(88.9%) had a combination of several postoperative complications. The occurrence of 
postoperative neurologic complications in this group of patients was particularly 
associated with hypertension and the presence of cerebrovascular disease in their 
medical histories (p < 0.05 and p < 0.001, respectively). Despite the differences 
between the clusters with respect to gender, age, and CPB duration (Table 5), we did 
not find a statistically significant association between these factors and postoperative 
neurologic complications in any of the clusters. 
 
Table 4 —Perfusion Parameters in Clusters* 
Parameter Parameter 
Properties 
Cluster No
1 (n = 389) 2 (n = 431) 3 (n = 348) 4 (n = 229) 
BFI, L/min/m Mean  2.4 ± 0.2 2.3 ± 0.2 2.3 ± 0.2 2.3 ± 0.2 
Dispersion 0.10 ± 0.07 0.13 ± 0.09 0.10 ± 0.07 0.19 ± 0.12 
Maximum 2.6 ± 0.2 2.6 ± 0.2 2.5 ± 0.2 2.6 ± 0.2 
Minimum 1.6 ± 0.6 1.4 ± 0.7 1.5 ± 0.6 1.3 ± 0.7 
MAP, mmHg Mean  56.3 ± 7.4 57.4 ± 6.5 75.0 ± 6.6 68.5 ± 8.7 
Dispersion 5.5 ± 2.2 8.6 ± 2.3 8.5 ± 2.5 13.7 ± 3.2 
Maximum 71.1 ± 10.0 77.1 ± 9.8 93.8 ± 9.5 97.2 ± 12.8 
Minimum 43.3 ± 9.2 38.1 ± 7.6 51.3 ± 10.2 38.3 ± 8.5 
APpulse, mmHg Mean  18.7 ± 6.6 22.5 ± 7.1 23.1 ± 7.6 26.5 ± 8.1 
Dispersion 2.5 ± 1.1 4.1 ± 1.6 3.4 ± 1.4 6.9 ± 2.6 
Maximum 24.3 ± 7.8 31.4 ± 9.2 30.5 ± 9.2 41.4 ± 14.1 
Minimum 8.6 ± 5.8 8.6 ± 5.6 9.1 ± 6.5 7.6 ± 5.1 
SVR,  
dyne ∙ s ∙ cm-5 
Mean  1,074 ± 168 1,178 ± 179 1,440 ± 192 1,455 ± 266 
Dispersion 115 ± 49 195 ± 66 177 ± 54 358 ± 126 
Maximum 1,672 ± 647 2,077 ± 1,174 2,209 ± 845 3,093 ± 1,860 
Minimum 810 ± 184 738 ± 191 955 ± 219 755 ± 197 
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Parameter Parameter 
Properties 
Cluster No
1 (n = 389) 2 (n = 431) 3 (n = 348) 4 (n = 229) 
 
Temperature, °C 
     
Arterial Mean  33.3 ± 2.5 31.1 ± 2.0 31.4 ± 1.9 31.2 ± 2.2 
Dispersion 1.5 ± 0.1 2.4 ± 1.0 2.2 ± 0.9 2.4 ± 1.1 
Maximum 36.3 ± 1.6 36.2 ± 1.6 36.4 ± 1.5 36.3 ± 1.7 
Minimum 30.1 ± 4.1 26.3 ± 2.9 27.4 ± 3.1 26.3 ± 3.9 
Rectal Mean  34.1 ± 1.9 32.2 ± 1.6 32.4 ± 1.6 32.1 ± 1.9 
Dispersion 0.6 ± 0.4 0.9 ± 0.4 0.9 ± 0.4 1.0 ± 0.6 
Maximum 35.4 ± 1.4 34.6 ± 1.3 34.7 ± 1.2 34.7 ± 1.6 
Minimum 33.3 ± 2.4 31.0 ± 2.0 31.2 ± 2.0 30.7 ± 2.6 
Pao2,  kPa Mean  119 ± 36 124 ± 43 117 ± 20 123 ± 36 
Dispersion 19 ± 11 21 ± 12 19 ± 7 24 ± 16 
Maximum 190 ± 84 197 ± 73 195 ± 60 210 ± 82 
Minimum 77 ± 35 77 ± 34 72 ± 19 74 ± 26 
Svo2, % Mean  71.3 ± 5.8 78.9 ± 5.1 77.2 ± 5.5 77.9 ± 6.2 
Dispersion 2.9 ± 1.2 3.8 ± 1.8 3.5 ± 1.3 4.1 ± 1.9 
Maximum 77.4 ± 5.2 85.5 ± 4.3 83.1 ± 4.9 85.2 ± 5.7 
Minimum 62.6 ± 7.0 67.8 ± 7.5 65.4 ± 7.5 65.2 ± 8.5 
*Values given as mean ± SD. The variables included in the cluster procedure (final cluster centers) are 
presented  in bold. 
 
Table 5 Demographic, Clinical, and Operative Characteristics of the Study Patients in Clusters* 
Variable Cluster No  
 1 (n = 389) 2 (n = 431) 3 (n = 348) 4 (n = 229) 
Age, yr 
BSA, m2 
62 ± 10
1.93 ± 0.2 
65 ± 9
1.89 ± 0.2 
61 ± 10
1.99 ± 0.2 
66 ± 9 
1.85 ± 0.2 
Obesity (BMI > 25) 71.3 65.7 76.4 62.7 
Female sex 27.1 29.9 11.5 37.6 
Previous cerebral incident 3.1 7.7 6.6 11.8 
CPB duration, min 65 ± 23 85 ± 33 90 ± 32 96 ± 38 
ACC duration, min 41 ± 16 54 ± 22 59 ± 23 59 ± 23 
Cardioplegia, mL/10 kg/min 3.0 ± 1.1 2.6 ± 0.9 2.3 ± 0.8 2.6 ± 0.9 
Distal anastomoses 3.3 ± 1.1 3.8 ± 1.1 3.9 ± 1.2 3.8 ± 1.1 
Postoperative neurologic complications 0.3 2.3 2 3.9 
Postoperative renal failure 3.6 5.8 5.2 9.6 
*Values given as mean ± SD or %. Only factors that significantly differed between clusters are presented.  
See Tables 1 and 2 for abbreviations not used in the text. 
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Discussion 
Neurologic complications after coronary artery bypass surgery substantially increase 
mortality, put a strain on health-care resources, and reduce the clinical effectiveness of 
the procedure [8,10,11]. Customarily, these complications have been attributed mainly 
to the effects of CPB [8]. Nowadays, complications associated with the use of CPB have 
gained even more attention due to the rediscovering and growing interest in “off-
pump” CABG. The reported incidence of neurologic complications after CABG with CPB 
varies from 0.8 to 3.2% in retrospective studies [1,12-14] and from 1.5 to 5.2% in 
prospective studies [2,15,16]. The frequency of severe postoperative neurologic 
disorders in the present study (1.9%) is in line with these previous findings. 
 Previous studies identified individual factors related to postoperative neurologic 
complications. Among them were age, gender, arterial hypertension, diabetes mellitus, 
carotid stenosis, previous cerebrovascular disease, preoperative and postoperative 
arrhythmias, requirement of using an intra- aortic balloon pump, duration of CPB and 
aortic cross clamping, and the number of anastomoses performed [8,14,17-22]. 
However, in most of these studies these factors were examined individually, which led 
to conflicting reports in the literature [15]. For example, some studies [8,18] have 
demonstrated that advanced age and previous cerebrovascular disease are powerful 
predictors of postoperative stroke, whereas others [3,4,23] have not found such an 
association. The results from our direct comparison of groups of patients with and 
without postoperative neurologic complications are consistent with those of the 
studies in which age and a history of cerebral stroke increased the probability of 
postoperative neurologic complications. Also, in the present study, the group of 
patients with postoperative neurologic complications had more distal anastomoses 
performed, and had longer CPB and cross-clamp times. However, other common risk 
factors were not significantly associated with the incidence of postoperative 
neurologic complications in the present. Gender, hypertension, carotid disease, and 
diabetes mellitus all were not directly associated with these complications. Our 
findings, however, support re- ports in which postoperative neurologic events were 
linked to the development of cardiac arrhythmias [24], myocardial infarction [25], or 
renal failure [25, 26]. 
 CPB is still an important, intrinsic part of coronary artery bypass surgery. Yet, data 
on the impact of apparently normal CPB procedures on the development neurologic 
complications are rare and usually are from studies performed in small, selected 
groups of patients. Furthermore, these studies were mainly focused on a single 
characteristic of CPB (e.g., temperature [27], pulsatility of flow [28], or acid-base 
management [29]). The multifactorial nature of neurologic complications after CPB 
makes the results of such investigations controversial. Determining “true” predictors 
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of postoperative neurologic complications is furthermore hampered by the small num-
number of outcome events in data collection [16, 30] and by the low incidence of 
major neurologic complications [1-4]. This and the multifactorial etiology of 
postoperative neurologic complications [31] do not favor the use of conventional 
statistical methods. The cluster analysis used in the present study was developed in 
the 1960s and has been used in studies of pattern recognition, artificial intelligence 
and neural network development, social sciences, and epidemiology [9]. Until now, 
however, this method rarely has been applied in clinical studies [31-34]. In the present 
study, the separation of large groups of similar CPB characteristics by means of cluster 
analysis enabled us to overcome the above-mentioned limitations. Despite the small 
number of patients with postoperative neurologic complications, the use of cluster 
analysis enabled us to study the interaction between risk factors for postoperative 
neurologic complications and CPB. Most of the known risk factors appeared not to be 
the ultimate, independent predictors that predispose CABG patients to postoperative 
neurologic complications, yet their impact showed to be altered by the performance of 
the CPB procedure. 
 In the present study, patients in the fourth cluster had the most frequent 
fluctuations of hemodynamic parameters, which resulted in an almost 10-fold increase 
of the risk for major postoperative neurologic complications compared to patients in 
the first cluster. Furthermore, in patients with cerebrovascular disease in their medical 
history who were included in the fourth cluster, the incidence of post- operative 
neurologic complications reached 22.2%. On the contrary, in the second cluster, in 
which 35% of all patients with cerebrovascular disease in their medical history were 
merged, none of the patients experienced a postoperative neurologic complication. 
Also, only in the fourth cluster was the development of major postoperative neurologic 
complications associated with a history of hypertension and/or cerebrovascular 
disease. Surprisingly, the occurrence of postoperative neurologic complications was 
associated with carotid disease only in patients in cluster 3. 
 The results of our direct comparison of groups with and without postoperative 
neurologic complications are consistent with those of studies in which age and 
duration of CPB and clamp-time are significant predictors of postoperative neurologic 
complications [15]. However, the impact of these factors dis appeared when we 
analyzed them using cluster analysis. However, what we found in the cluster analysis, 
as well as in a direct comparison of groups with and without neurologic complications, 
was a strong association of postoperative neurologic complications with other 
postoperative complications. The development of severe postoperative neurologic 
events in all but the first clusters was statistically related to at least one coexistent 
complication. However, the interrelationship of these events makes the identification 
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of the relative contribution of each single variable difficult. Therefore, further studies 
are necessary to elucidate the relationship of these complications. 
In conclusion, this study shows that apparently normal CPB procedures affect the 
impact of common clinical risk factors on postoperative neurologic complications. 
Particularly, patients who underwent CPB procedures with large fluctuations in 
hemodynamic parameters showed an increased risk for the development of 
postoperative neurologic complications. 
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Abstract 
 Background: Patients undergoing cardiac surgery with the use of cardiopulmonary 
bypass (CPB) are often thought to have tissue hypoxia and intraoperative oxygen debt 
accumulation despite the lack of sufficient data to support this assumption. 
 Methods and results: Oxygen uptake and related parameters, including the plasma 
lactate and pyruvate concentrations, were studied during the perioperative period in a 
group of 15 consecutive patients who underwent coronary artery bypass graft surgery. 
The actual oxygen uptake (VO2) and delivery (DO2) were compared with the individual 
expected (computed) oxygen transport values. The mean values of DO2 and VO2 were 
in the range of the expected values. Our results demonstrate a leading role for body 
temperature in perioperative changes of oxygen consumption rate (r2=0.65, p<0.001). 
Plasma lactate and pyruvate did not exceed the physiological range in any patient. 
However, with initiation of CPB, the lactate to pyruvate (LA/PVA) ratio increased (from 
9.87 +/- 2.43 at T1 to 12.08 +/- 1.51 at T2, p<0.05). The mean value of the LA/PVA ratio 
was elevated during surgery. Later, upon lowering of the plasma lactate concentration 
in the postoperative period, the LA/PVA ratio decreased to normal values. Without any 
other evidence of hypoxia, this increase in the LA/PVA ratio could be explained by 
washout of lactate from previously hypo-perfused tissues and intraoperative decrease 
of lactate clearance. 
 Conclusion: Systemic oxygenation was not impaired during CPB or during 18 h 
after surgery in the studied group of patients. 
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Introduction  
Patients undergoing cardiac surgery with the use of cardiopulmonary bypass (CPB) are 
often thought to have tissue hypoxia and intraoperative oxygen debt accumulation [1-
4]. The development of tissue hypoxia and oxygen debt has several attributes. A 
biphasic response with reduced oxygen consumption (VO2) and reduced cardiac 
output (CO) during surgery, followed by an increment of values of these parameters in 
the postoperative period [5, 6] is the fundamental syndrome of the oxygen debt 
theory. The association between oxygen delivery and consumption is another 
recognized symptom of oxygen debt state [2, 4, 7-11]. Recently, however, most of 
these reports have been criticized because of their methodology [12, 13]. 
 This study was initiated in order to determine the existence and causes of the 
oxygen debt during cardiac surgery. To find out if, in fact, there is a general tissue 
hypoxia and intraoperative oxygen debt accumulation in cardiac surgical patients, 
oxygen uptake and related parameters were studied during the intra- and 
postoperative periods in a group of patients who underwent coronary artery bypass 
graft (CABG) surgery. Actual oxygen uptake and delivery were compared with the 
individual expected (computed) oxygen transport parameters in order to calculate the 
oxygen consumption deficit time curve. Additionally, we studied the dynamics of lactic 
acid and pyruvate concentration in the same period. 
Methods 
The study was performed in 15 consecutive patients (12 male and 3 female), aged 61.1 
± 8.9 years (mean ± SD). All selected patients underwent elective CABG surgery and 
preoperatively they were in New York Heart Association (NYHA) class III or IV. Patients 
with hepatic or renal insufficiency, diabetes mellitus or thyroid diseases, severe 
hypertension, or a history of neurological disorder were excluded from the study. 
Patients with heart failure or rethoracotomy after surgery were also excluded from 
further investigation. The local ethical review board approved the study. The study was 
observational and did not involve any intervention beyond normal management. For 
this reason, a written informed consent was not required.  
 The conduct of anaesthesia and CPB was done by standard hospital practice. The 
patients received general anaesthesia. Induction: midazolam (0.06 - 0.08 mg/kg), 
sufentanyl (1 - 1.5 mg/kg); neuromuscular blockade: pavulon (0.1 mg/kg); 
maintenance: sufentanyl (0.5 - 1.25 mg/kg/h), or/and propofol infusion (3 - 6 
mg/kg/h). 
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 The bypass circuit consisted of a hollow-fibre oxygenator (Univox™, Bent-
ley/Baxter, Irvine, CA, USA or Capiox SX Terumo, Tokyo, Japan), an arterial line filter 
(Pall Biomedical, Portsmouth, UK) and a roller pump (Stöckert Instruments, Munich, 
Germany). The circuit was primed with a mixture of Haemaccel (3.5%, 1200 ± 1300 ml), 
mannitol (20%, 200 ml), human albumin (20%, 100 ml), and NaHCO3 (8.4%, 50 ml), 
potassium chloride (20 mmol), and heparin (50 mg/1000 ml prime). CPB was carried 
out by means of pulsatile flow with a flow range of approximately 2.4 l/min/m2. Mod-
erate hypothermia (28 - 32°C) was applied during perfusion. Modified St. Thomas solu-
tion was used to arrest the heart and to maintain an iso-electrical state of the heart. 
After release of the aortic clamp, a nitroglycerine infusion (0.5 mg/kg/min) was start-
ed. 
 After surgery and return to the intensive care unit, standard patient management 
protocols were applied. Patients were weaned from mechanical ventilation as soon as 
haemodynamic and respiratory stability had been established and they were awake 
and orientated in space and time. 
 
 
Figure 1. The study stages and their relation to the perioperative events. T1 - before systemic 
heparinization; start of CPB (T2); every 20 min of bypass (T3a…Tn); before removal of the aortic 
crossclamp (T4); 15 min after protamine infusion (T5); 2, 4, 8, 12, and 18 h after the end of 
operation (T6… T10). 
 
Haemodynamic measurements, arterial and mixed venous blood samples were taken 
at 10 time intervals during surgery and up to 18 h in the postoperative period (Figure 
1). Haemodynamic measurements consisted of arterial blood pressure, central venous 
pressure, and cardiac output, measured by the thermodilution method. The blood flow 
rate during total bypass was used for oxygen transport calculations in place of cardiac 
output. At all time periods, we also collected blood for measurement of haemoglobin 
concentration, arterial and mixed venous oxygen tension and saturation (ABL4; 
Radiometer, Copenhagen, Denmark). Lactate and pyruvate concentrations in the blood 
were measured at all time periods, excluding T3a…Tn. The venous blood temperature 
during CPB and pulmonary artery temperature in all other periods were assumed to 
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represent the `mean core’ temperature. During the study, special attention was given 
to simultaneous measurement of haemodynamic parameters and the collection of 
blood samples. 
 Formulae used to calculate oxygen transport and related parameters are given in 
Appendix. 
 Linear regression analysis was applied to express the oxygen consumption as a 
function of the oxygen delivery and body temperature. Wilcoxon matched- pairs 
signed-ranks tests were used to determine whether the changes in oxygen uptake and 
related variables were significant. All statistical analyses were performed with SPSS 7.5 
for Windows. A p value of less than 0.05 was considered significant. All values in the 
tables and the text are presented as mean ± SD. 
Results 
The characteristics of the patients enrolled in the study are presented in Table 1. All 
patients were haemodynamically stable after surgery, i.e., during the 18 h of the study 
period. They all were awake and most of them were extubated at 12 h post-surgery. 
The mean time to extubation was 12 h, with a range from 5 to 17 h after surgery. Two 
patients had a short period of atrial fibrillation treated by medication. 
 
Table 1 Characteristics of patients and operation conditions (n=15) 
Parameter Value (mean± SD)
Age (years) 61.1± 8.9
Male/Female 12/3
BSA (m2)* 1.90 ± 0.15
Duration of CPB (min) 77.9 ± 23.4
Crossclamp time (min) 49.9 ± 18.8
Time to extubation (min) 721 ±183
*BSA=body surface area. 
 
The systemic vascular resistance (SVR) was in the physiological range throughout the 
study period (Table 2). During the initiation of CPB, the SVR declined (from 1157.9 
±195.1 dyn∙s/cm5 at T1 to 924.7±213.7 dyn∙s/cm5 at T2, p<0.05). This, together with 
the decrease in blood flow, leads to a sharp lowering of the mean arterial pressure 
(from 78.97 ± 8.43 mmHg at T1 to 56.27 ± 13.36 mmHg at T2, p<0.001). Later, during 
cooling, the SVR rose to the pre-perfusion level or higher. However, with the initiation 
of rewarming (T4), the vascular resistance started to decline and reached its lowest 
value after the end of perfusion (T5). A tendency to low vascular resistance was 
observed during the first 18 postoperative hours in each patient. At the same time, the 
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mean arterial pressure was around 70 mmHg because of a relatively high cardiac out-
output (2.7 - 3.5 l/min/m2). 
 
Table 2 Haemodynamic characteristics before, during, and up to 18 h after coronary bypass operation (n=15 
patients) 
 Mean arterial blood pressure (mmHg) 
Blood flow index
(l/min/m2) 
Systemic vascular 
resistance (dyn∙s/cm5) 
T1 78.97±8.43┼ 2.67 ± 0.36* 1157.9 ± 195.1* 
T2 56.27±13.36* 2.41 ± 0.08 924.7 ± 213.7* 
T3a 67.33 ± 10.51* 2.35 ± 0.20 1148.7± 143.4* 
T3b 80.8 ± 7.25 2.37 ± 0.11 1315.1 ± 154.6 
T4 70.78 ± 12.95 2.41 ± 0.21* 1171.3‹194.8* 
T5 70.20 ± 6.86 3.09 ± 0.75 893.5 ± 271.4* 
T6 74.37 ± 8.54* 2.70 ± 0.46* 1110.2 ± 261.1 
T7 68.6 ± 9.48 3.04 ± 0.43 900.4 ± 225.7 
T8 77.27 ± 14.34 3.45 ± 0.75 912.0 ± 298.6 
T9 70.87 ± 12.40 3.14 ± 0.48 876.9 ± 220.6* 
T10 75.86 ± 9.64 3.00 ± 0.40 917.3 ± 354.5 
*p<0.05 compared with next interval. ┼p<0.01 compared with next interval. 
 
Oxygen delivery (DO2) in the patients (Figure 2) was significantly above the critical level 
at the start of operation (p<0.001) and during the major part of the CPB (p<0. 05, T2, 
T3a, T3b). However, before removal of the aortic cross clamp (T4), the oxygen delivery 
rate entered the estimated critical area (263.1 ± 22.5 versus 243.5 ± 37.3 ml/min/m2, p 
> 0.05) and also, the oxygen delivery decreased, close to a critical value at 2, 12, and 18 
h after the end of operation (T6, T9, and T10 respectively, p>0.05). 
 The mean value of the oxygen consumption in this group of patients (Figure 3) 
was in the range of the expected oxygen consumption during surgery and up to 18 h 
after (p>0.05). The oxygen extraction ratio (O2ER) during the study period was lower 
than the critical value. Although the mean value of O2ER at the start of the operation 
and during CPB was relatively low (20.8 ± 5.1%, T2), it began to rise at the end of 
surgery and reached its maximum at 12 - 18 h after operation (31.5 ± 9.4% and 30.1 ± 
6.1%, T9 and T10, respectively). The difference between the expected and the 
measured oxygen consumption plotted against the time between two sample points 
gives the oxygen consumption deficit time curve. The mean value of the consumption 
deficit was close to zero during the study period. 
 The mean value of the net oxygen debt to the end of CPB (T1…T5) was 418.4 ± 
678.2 ml O2/m
2 and increased to 710 ± 1068.2 ml O2/m
2 at the end of surgery (T1…T6). 
The mean value of oxygen consumption changed parallel to the body temperature. 
The minimum values of both parameters were observed during CPB (T3a and T3b). The 
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VO2 reached a maximum at 8 h after surgery (T8). The body temperature reached its 
value (38.22 ± 0.47°C) at the same time. The regression analysis from pooled data 
showed a high exponential correlation between oxygen consumption rate and body 
temperature (Figure 4; VO2 = 1.3685∙exp(0.1155∙T°C), r2=0.65, p<0.001). 
 
 
Figure 2 Oxygen delivery before, during, and up to 18 h after coronary bypass operation. 
The grey area is the critical level of oxygen delivery.  
 
 
Figure 3. Oxygen consumption before, during, and up to 18 h after coronary bypass 
operation. The grey area is the expected level of oxygen consumption (p>0.05 for all 
samples points). 
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Figure 4 Whole body temperature and oxygen consumption pooled from all study periods 
(T1…T10). 
 
The oxygen consumption was also related to the oxygen delivery rate. The regression 
analysis for the pooled data showed a linear relationship between DO2 and VO2: VO2 
=0.27 ∙ DO2 - 6.27, r2 = 0.49, p<0.01. However, the regression analysis for each study 
period failed to show any significant relation between DO2 and VO2 during surgery 
(T1…T5) and 8 and 12 h after operation (T9, T10). These two parameters were 
statistically significantly different only during the first hours after surgery (at T6, 
r2=0.57, p<0.001; at T7, r2=0.36, p<0.01; at T8, r2=0.715, p<0.001). 
 Plasma lactate and pyruvate levels did not exceed the physiological ranges in any 
patient at any study time interval (Table 3). During the initiation of CPB the plasma 
lactate concentration significantly increased and reached a plateau after 20-30 min, 
after which it remained unchanged until the end of the surgery. Two hours later (T6), 
the lactate concentration had already decreased to the pre-bypass level. The PVA 
concentration was increased significantly after 60 min of CPB, compared to the pre-
bypass level (121.0 ± 44.9 mmol/l at T4 and 105.7 ± 41.5 mmol/l at T1, p<0.05). In the 
postoperative period, up to 18 h, the mean value of the PVA concentration did not 
change significantly. 
 The LA/PVA ratio dramatically increased during the initiation of CPB (from 9.87 ± 
2.43 at T1 to 12.08 ± 1.51 at T2, p<0.05). The mean value of the LA/PVA ratio was 
elevated (more than 10×) during surgery. However, due to lowering of the plasma 
lactate concentration during the first 2 h in the postoperative period, the LA/PVA ratio 
decreased to normal values. 
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The mixed venous pH also decreased during the initiation of CPB, but stayed in the 
normal range during the entire study (Table 3). 
 
Table 3 pH, lactate, pyruvate, and lactate/pyruvate ratio before, during, and up to 18 h after coronary 
bypass operation (n=15 patients)  
 pHv LA (mmol/l) PVA (mol/l) LA/PVA 
T1 7.39 ± 0.02┼ 1.00 ± 0.39┼ 105.7 ± 41.5 9.87 ± 2.43* 
T2 7.36 ± 0.02 1.19 ± 0.46 98.1 ± 34.9┼ 12.08 ± 1.51 
T3a 7.34 ± 0.04 1.43 ± 0.29 - -
T3b 7.35 ± 0.04 1.40 ± 0.42 - -
T4 7.35 ± 0.04 1.41 ± 0.44 121.0 ± 44.9 12.03 ± 1.5* 
T5 7.36 ± 0.04* 1.41 ± 0.38* 129.3 ± 37.6 11.11 ± 1.95* 
T6 7.40 ± 0.05 1.04 ± 0.33 111.7 ± 46.5 9.71 ± 2.03 
T7 7.39 ± 0.04 1.02 ± 0.40 113.5 ± 49.2 9.27 ± 1.31* 
T8 7.36 ± 0.04 1.01 ± 0.35 133.7 ± 57.6 8.04 ± 1.91 
T9 7.36 ± 0.04 1.11 ± 0.45 145.7 ± 67.4 7.92 ± 1.67 
T10 7.35 ± 0.03 1.39 ± 0.66 155.6 ± 75.0 9.45 ± 3.26 
pHv, mixed venous pH; LA, plasma lactate; PVA, plasma pyruvate; LA/PVA, lactate/pyruvate ratio. *p<0.05 
compared with next interval.  ┼ p<0.01 compared with next interval. 
Discussion 
Optimal oxygen delivery and consumption in the perioperative period are essential in 
order to reduce immediate morbidity and mortality after open-heart surgery [2]. If 
oxygen delivery is below a critical level, the oxygen consumption will simultaneously 
decrease linearly. In this situation, the oxygen delivery is inadequate to prevent tissue 
hypoxia and development of the oxygen debt. Oxygen debt is considered as an 
important factor in determining the outcome of surgical patients, as well as critically ill 
patients [2, 8, 14 - 16]. However, most of these reports have been criticized because of 
their methodology [12, 13]. There have also been a number of reports that refute the 
existence of supply dependence in critically ill patients or during surgery [12, 17 - 19]. 
Several clinical studies in high- risk surgical patients showed a biphasic response, with 
reduced oxygen consumption and reduced cardiac output during surgery followed by 
an increase of CO and VO2 in the postoperative period [5, 6, 20]. This biphasic response 
is independent of the type of operation, and represents the periods of accumulation 
and repayment of an oxygen debt. It appears that our data showed this biphasic 
response with a reduction of oxygen delivery and consumption during surgery and, 
subsequently, an increase in the postoperative period. However, comparison of these 
parameters with the expected individual delivery and consumption disproves this 
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assumption (Figures 2 and 3). At all time intervals, the mean values of DO2 and VO2 
were in the expected range when corrected for the patient’s body temperature, level 
of anaesthesia, and muscle relaxation. Also, the oxygen extraction ratio was lower than 
reported critical values [21]. 
 However, from the first hours after surgery, the oxygen extraction ratio began to 
rise and reached its maximum at 12 - 18 h after operation (31.5 ± 9.4% at T9 and 30.1 ± 
6.1% at T10). This could indicate some stress in the oxygen transport system, probably 
related to the increase of the body temperature and the extubation of the patient. 
 One other recognized indicator of oxygen debt is the VO2 dependency on the DO2. 
Some reports are presenting a strong association between VO2 and DO2 in cardiac 
surgical patients [7, 22]. In contrast to these findings, we could not reveal any 
correlation between VO2 and DO2 during CPB. Significant VO2 dependence on the DO2 
was found only in the pooled data from the entire study. However, this VO2/DO2 
relationship in a select subpopulation, such as the presented group of patients, may be 
a result of an artificial correlation due to a third type of mathematical coupling [23]. If 
a true relationship is to be found between VO2 and DO2, it must be determined by 
using an independently obtained VO2 from the expired gas analysis. Such a study was 
done by Myles et al. [18], and the authors failed to show any significant relationship 
between changes in DO2 and VO2 peri-operatively. Our results seem to demonstrate a 
leading role of body temperature changes in relation to the perioperative changes in 
the oxygen consumption rate. A peak in the VO2 was recorded at a time when the 
maximum body temperature occurred. Also, the pooled data showed a strong 
exponential correlation between the body temperature and the total oxygen 
consumption (Figure 4; r2=0.65, p<0.001). 
 Measurement of acidosis, base deficit, and blood lactate levels is providing more 
objective information. Lactate is an end product of anaerobic metabolism and is in a 
dynamic equilibrium with its precursor, pyruvate. The LA/PVA ratio is related to the 
redox state of the cell, which is a function, in part, of the adequacy of oxygen delivery 
[24]. The ratio of serum lactate to pyruvate concentrations in arterial blood is normally 
less or equal to 10:1. Lactate/pyruvate ratios >10:1 suggest that the DO2 is inadequate 
to meet the metabolic demand [25]. However, newer data suggest that lactate could 
accumulate under aerobic conditions in clinical settings [24]. Calcium, insulin, and 
magnesium stimulate PDH phosphatase, which catalyzes phosphorylation of PDH and 
its deactivation, which consequently leads to formation of more lactate anions [24]. 
The washout of lactate from peripheral tissues [26, 27] and a decreased lactate 
clearance [10] can complicate even more the interpretation of intraoperative findings. 
 The rise of the LA/PVA ratio just after the initiation of the CPB could indicate 
impaired tissue perfusion, although these findings (9.87 ± 2.43 at T1 and 12.08 ± 1.51 
at T2, p<0.05) are more likely related to the sharp changes in the haemodynamics 
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rather than switching to anaerobic metabolism. Haemodilution of 25 - 35% after the 
mixing of the prime (1600 ml) with the patient’s blood is the most likely explanation of 
the significant decrease in the PVA concentration (Table 3; p<0.001). On the other 
hand, lactate concentration does increase in the early phase of CPB, but this increase 
did not exceed the normal levels of lactate concentration (2 mmol/l). Common 
vasoplegia during the first 10 - 15 min of CPB, together with haemodilution, could 
increase the washout of lactate from previously hypo-perfused tissues [26, 27]. There 
is one more mechanism that could be involved in maintaining the relative excess of 
lactate during cardiac surgery, an intraoperative decrease of lactate clearance. The 
myocardium, which is an important consumer of lactate [24, 28], is excluded from the 
circulation during most of the surgery time. The absence of any significant degree of 
metabolic acidosis during our study may additionally confirm a lack of anaerobic 
metabolism and oxygen debt during surgery and up to 18 h thereafter. 
 The analysis of data reveals the fact that the oxygen debt theory could not explain 
our findings. Alternatively, our data indicate that the changes in body temperature 
during and after surgery in the studied group of patients create the illusion of biphasic 
response with a reduction of oxygen delivery and consumption during surgery and an 
increase in the postoperative period. 
Conclusion 
We conclude that, in the studied group of patients, systemic oxygenation was neither 
impaired during CPB, nor in the first 18 h after surgery. Some stress of the oxygen 
transport system was found in the period 12 - 18 h after surgery, which is probably 
related to the increased body temperature and extubation of the patients. 
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Appendix 
The DO2 in each case was calculated as the product of arterial oxygen content (ConO2a, 
ml O2/100 ml blood) multiplied by the perfusion flow (CI, l/min/m
2): 
 
 DO2 (ml/min/m
2) = ConO2a ∙ CI ∙ 10  (1) 
 
The oxygen content in blood is the sum of oxygen carried by haemoglobin and 
dissolved in plasma: 
 
ConO2 = Hb ∙ SO2 ∙ 1.32 + PO2 ∙ ZO2 (2) 
 
where: Hb - haemoglobin content of blood (g%); SO2 - oxygen saturation of blood (U); 
1.32 - binding coefficient; PO2 - oxygen partial pressure (atm); ZO2 - solubility 
coefficient of oxygen at actual blood temperature (ml oxygen/100 ml blood). 
 The oxygen solubility coefficient (ZO2) was computed using the regression 
equation published by Riley et al. [29] in 1983. This equation gives a strong correlation 
with measured values published by Christoforides and Hedley-Whyte [30] in 1960:  
 
ZO2 = [(4 ∙ Hb + 346) ∙ T + (130 ∙ Hb + 35000)] ∙ 0.0001/760 (3) 
 
where: Hb - haemoglobin content of blood (g%); T - blood temperature (°C). 
 
 The critical level of oxygen delivery (DO2crit) in normothermic anaesthesized patients 
was determined as 300 - 330 ml/min/m2 [2, 11, 31]. The hypothermia during CPB 
exponentially decreases the tissue metabolic rate and correspondingly the oxygen 
consumption rate. It is logical to assume that the critical level of oxygen delivery 
changes with the decrease in tissue metabolic rate. The oxygen delivery of 330 
ml/min/m2 was taken as a value of DO2crit for anaesthesized patients at 37°C body 
temperature. The regression equation (Equation 4) was used to compute the 
temperature correction coefficient: 
 
Coef = exp[(0.08329∙T + 1.5234)/100)] (4) 
 
The last equation (Equation 4) was suggested by Riley et al. [29] in 1983. The individual 
value of the critical level of oxygen delivery was calculated for each patient according 
to the body temperature. The critical area of oxygen delivery for our group of patients 
was defined as an area between mean+SD (upper limit) and mean-SD (lower limit) of 
DO2crit computed for each patient at correspondent study point. 
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The VO2 in each case was calculated as a product of arterial - venous difference multi-
plied by the blood flow: 
 
VO2 (ml/min/m
2) = (ConO2a - ConO2v) ∙ CI ∙ 10  (5) 
 
The calculation of expected oxygen consumption was based on published results of 
large population studies of human basal metabolic rate. In this work, the linear 
equations derived by Riley et al. [29] were used for males: 
 
VO2exp (ml/min/m
2) = exp(0.003907∙A+5.034)  (6) 
 
for females 
 
VO2exp (ml/min/m
2) = exp(0.002806∙A+4.8934)  (7) 
 
where: A - age (years). 
 
The induction of anaesthesia and muscle relaxation causes a decrease in whole body 
oxygen consumption to 80-85% from the expected due to the lowering of functional 
requirement [32]. Decreasing oxygen demand during CPB is also caused by induction of 
hypothermia. The effect of temperature on expected oxygen consumption was shown 
in Equation (4). 
 The myocardial oxygen consumption in adults at rest, according to non-published 
data collected by Loer et al. [33] (University Hospital Maastricht, 1998), is 5.3 ± 0.23 
ml/min/m2 and the lungs consume about 5% of the whole body oxygen uptake. 
Excluding the myocardium and lungs from the circulation explains up to 10% of the 
decrease in whole body oxygen consumption during the cross clamp time. 
 The final value of expected oxygen consumption during total bypass appears to be 
25 - 30% lower than that derived using Equation (6) or Equation (7). The expected level 
of oxygen consumption for our group of patients was defined as an area between 
mean+SD (upper limit) and mean-SD (lower limit) of VO2exp computed for each patient 
at the corresponding study point. 
 The oxygen debt was calculated from the difference between the actual measured 
VO2 and the individual O2 requirements corrected for both anaesthesia [32] and 
temperature [29]. Then, the net cumulative VO2 deficit was computed as an integrated 
area under the VO2 deficit-time curve [2].  
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CHAPTER 4 
The effect of oxygenator mechanical 
characteristics on energy transfer during 
clinical cardiopulmonary bypass 
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Abstract 
The hollow-fibre oxygenator is a key component of any extracorporeal circuit used to 
provide cardiopulmonary bypass (CPB) during open-heart surgery. Since the 
oxygenator is placed downstream the pump, the energy losses over it have a direct 
impact on the quality of pulsatile pressure and flow waveforms. The objective of this 
study was to describe the effects of hydrodynamic characteristics of oxygenator on 
energy transfer during pulsatile, normothermic CPB. 
 Twenty-three adult patients scheduled for coronary bypass surgery were 
randomly divided in two groups using either an oxygenator (group 1) with a relatively 
high-resistance, low-compliance (2079 ± 148 dyn⋅s⋅cm-5 and 0.00348 ± 0.00071 
ml⋅mmHg-1, respectively) or an oxygenator (group 2) with a relatively low-resistance, 
high-compliance (884 ± 464 dyn⋅s⋅cm-5 and 0.01325 ± 0.00161 ml⋅mmHg-1, 
respectively). During perfusion, pre- and post-oxygenator pressures, radial artery 
pressure, and blood flow were recorded simultaneously. 
 A 32% decline of mean pressure was observed in group 1 and a 16% decline in 
group 2 (p<0.0001). Another decrease by approximately 73% in mean pressure in the 
rest of the perfusion system was noted in both groups. The mean radial artery 
pressure did not differ between the groups (74 ± 6 mmHg in group 1 and 73 ± 6 mmHg 
in group 2, p=0.608). Although lower total energy transfer indices were noticed 
through the low-resistance oxygenator (group 2), both oxygenators showed a decrease 
of the generated pump oscillatory energy of approximately 50%. 
 Despite the differences in resistance and compliance of the hollow-fibre 
oxygenators used, both oxygenators cause a comparable loss of generated oscillatory 
energy. Exclusion of the oxygenator downstream the pulsatile pump would improve 
energy transfer during CPB.  
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Introduction 
The debate on pulsatile flow during cardiopulmonary bypass (CPB) has continued for 
more than half a century. A recent PubMed database search on the topic revealed 
2,816 articles between 1967 and 2006 [1]. Although the subject has been discussed 
frequently during the past decades, results of the associated studies are controversial 
[2-5]. There are several reasons for dichotomy of results in comparative studies. The 
most important reason is methodological in nature. Many studies lack precise 
quantification of pressure and flow waveforms [3-8]. The broadly used term ‘pulsatile 
CPB’ in clinical trials is most often characterized only by heart-lung machine settings or 
by arterial pulse pressure, not by objective quantitative measures. Moreover, the 
enormous variety of blood flow indices, flow dynamics, and temperature regimes used 
in these studies, make the results often non-comparable and incoherent. Variations 
due to differences in characteristics and condition of the systemic vascular bed of 
patients are rarely assessed and, therefore, limit comparison even more. 
 Another reason for the lukewarm reception and skepticism of pulsatile CPB is the 
limited efficiency of the pumps used. For example, a roller pump is able to produce 
only 12.4% pulsatile power output compared to the heart [9]. Furthermore, in clinical 
practice a pulsatile regime is often not employed to its best advantage [10]. The 
complexity of the problem is also in the obvious conflict of interests of pulsatile flow 
and membrane oxygenation [11], and pulsatile flow and size of the arterial cannula 
[12] or pulsatile flow and length of the arterial line [13]. In addition, it is possible that, 
considering the complex physiological effects of pulsation, not only stroke volume is 
important but also the flow waveform (i.e. acceleration time and peak flow). 
 The hollow-fibre membrane oxygenator is a key component of any extracorporeal 
circuit used to provide CPB during open-heart surgery. Oxygenators are placed 
downstream from the arterial pump so that blood is pushed through the oxygenator. 
As a result, its mechanical properties have a direct impact on the quality of the 
pulsatile pressure and flow waveforms [14-16]. Some oxygenators dampen the pulse 
wave to a significant extent [11, 17]. It is generally accepted that an oxygenator with a 
lower pressure drop results in better flow pulsatility [16]. The aim of the present study 
was to describe the transmission of energy through two distinct hollow-fiber 
oxygenators during pulsatile, normothermic CPB. 
Materials and methods 
Twenty-three adult patients undergoing elective coronary bypass surgery were 
included in the study, and were randomly assigned to two groups. The study protocol 
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was approved by the Medical Ethical Committee of the Maastricht University Medical 
Centre. Written informed consent was obtained from all patients included. The study 
was registered in the Dutch Trial Register, trial number NTR1346.  
 In group 1 (n=12), a high-resistant, low-compliant hollow-fibre oxygenator (Capiox 
SX18, Terumo Cardiovascular Systems, Tokyo, Japan) was used. Group 2 (n=11) was 
assigned to a low-resistant, high-compliant hollow-fibre oxygenator (Quadrox BEHMO 
2000, Maquet Cardiopulmonary AG, Hirrlingen, Germany). In all cases, the 
extracorporeal system consisted of a Sorin S3 heart-lung machine (Sorin, S.p.A. Milano, 
Italy), a Bioline coated custom tubing pack (Maquet Cardiopulmonary AG), a 1/2-inch 
medical grade silicone arterial pump tubing, an arterial line filter (Leukoguard-6, Pall, 
East Hills, NY, USA), collapsible venous reservoir (JVR 1900, Maquet Cardiopulmonary 
AG), and a cardiotomy reservoir (Capiox SX hard-shell reservoir, Terumo Cardiovascular 
Systems). Occlusion setting of the arterial roller pump was set statically against a back-
pressure of 260 mmHg. The occlusion setting was verified before every use. Central 
cannulation was applied in all cases. 
 The instantaneous flow at the inlet and outlet of the oxygenator was measured 
using ultrasonic clamp-on flow probes (H9XL, Transonic Systems Inc., Ithaca NY, USA). 
Pressure was measured at the inlet and outlet of the oxygenator close to the flow 
probes and in the radial artery, using pressure transducers (PX604, TruWave, Edwards 
Lifesciences, Irvine, CA 92614, USA). Electronic data were acquired with a sampling 
frequency of 250 Hz, using a programmable PC-based acquisition system (MPAQ 
amplifier with IDEEQ software, Instrument Development Engineering & Evaluation, 
Maastricht University Medical Centre, Maastricht, the Netherlands). 
 The perfusion system was primed with 1,500 ml of colloidal solution. The 
management of normothermic perfusion was standardized by clinical practice. The 
mean arterial pressure was maintained around 75 mmHg with infusion of 
phenylephrine, if necessary. Pulsatile perfusion was initiated after aorta clamping. 
Pulsatile flow was set to 5.0 l.min-1 with a frequency of 72 beats per minute, a base 
flow of 28% (1.4 l.min-1), and a pulse width of 0.42 s (50% duty cycle). The pressure and 
flow waveform data were used to calculate quantitative parameters for the description 
of pulsatile perfusion. All parameters were computed and averaged over five-minute 
time intervals. 
Mechanical oxygenator characteristics 
Compliance  
Compliance describes the volume buffering capacity of a distensible compartment and 
is expressed as the ratio of the change in volume (∆V) divided by the change in 
pressure (∆p) [18]. 
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The static compliance of oxygenators used in this study was computed from the pres-
sure-volume relation. Pressure-volume relations were obtained in vitro after careful 
priming of the oxygenators. The pressure in the oxygenator was first increased from 0 
to 1,000 mmHg by injection of 0.9% sodium chloride solution in steps of 1 ml. Then the 
pressure was stepped down back to 0 mmHg. Compliance is calculated as: 
 
C = ∆V /∆p 
 
with C, compliance (ml.mmHg-1); ∆V, volume change (ml); ∆p, pressure change 
(mmHg).  
 The Quadrox BEHMO 2000 oxygenator had a significantly higher static compliance 
than the Capiox SX 18 oxygenator (0.01325 ± 0.00161 ml⋅mmHg-1 versus 0.00348 ± 
0.00071 ml⋅mmHg-1, p<0.0001). 
Resistance  
Resistance is computed from the clinical data as the mean pressure drop divided by 
the mean flow through the oxygenator, as: 
 
R = 79.9⋅(p0 - p1)/Q 
 
with R, hydrodynamic resistance (dyn⋅s⋅cm-5); p0, average inlet pressure (mmHg); p1, 
average outlet pressure (mmHg); 79.9, is the constant to convert from millimetres of 
mercury to dynes per square centimetres and flow from l per min to ml per second 
(1,332∙60/1,000); Q, average flow (l⋅min-1). The resistance of the Capiox SX 18 was 
significantly higher than the resistance of the Quadrox BEHMO 2000 (2,079 ± 148 
dyn⋅s⋅cm-5 and 884 ± 464 dyn⋅s⋅cm-5, respectively, p <0.0001).  
Quantification of pulsatile perfusion 
Energy Equivalent Pressure 
Shepard’s energy equivalent pressure (EEP) is defined as hemodynamic energy per unit 
volume of fluid pumped. EEP was computed as the ratio of the area beneath the 
hemodynamic power curve and the pump flow curve during each pulse cycle [3, 19-
22]:  
 
EEP = 
׬ ܳ(߬)݌(߬)݀߬௧଴
׬ ܳ(߬)݀߬௧଴
൙  
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with Q, pump flow rate (l.min-1); p, arterial pressure (mmHg). The time integrals are 
over a single pulse cycle. EEP is expressed in mmHg. 
Surplus hemodynamic energy 
Surplus hemodynamic energy (SHE) is the additional energy due to pulsatility in 
pressure or flow. SHE is defined as [21, 24]:  
 
SHE (mmHg) = (EEP - pmean) 
 
with EEP, energy equivalent pressure (mmHg); pmean, mean pressure (mmHg). Similarly 
to fractional pulse pressure [25, 26], we computed the fractional energy excess (FEE) 
as the ratio of the SHE and pmean. 
Pressure energy  
Pressure energy is a kind of potential energy. Potential energy per unit time is a 
product of the pressure and the volume rate of blood flow at any instant [27]. The 
total pressure energy is calculated as the area beneath the hemodynamic power curve 
[3, 19, 28]: 
 
 ࢃ࢚ = ૚ࢀ ׬ ࡽ(࣎) × ࢖(࣎)ࢊ࣎
ࢀ
૙  
 
where Wt, total pressure energy (W
.s-1); T, the period for the numeric evaluation of the 
integral; Q(t), the instantaneous measured flow rate (l.min-1); p(t), instantaneous 
pressure (mmHg). 
 Two components of total pressure energy are discriminated: the steady 
component Ws (the energy that would exist if there were no oscillations around the 
mean) and the oscillatory (pulsatile) component Wo.  
 Ws is calculated by multiplying mean pressure and mean flow [3, 18, 27]:  
 
Ws = pm 
.Qm 
 
with pm, mean pressure (mmHg); Qm, mean flow (l/min).  
The oscillatory pressure energy is calculated as the difference between the total 
pressure energy and the steady component: 
 
Wo = Wt - Ws 
 
with Wo, oscillatory pressure energy (W
.s-1); Wt, total pressure energy (W
.s-1); Ws, 
steady component (W.s-1). 
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Statistical analysis 
The Mann-Whitney U test with exact two-tailed calculation of p-values was used for 
comparison of variables between two groups (SPSS version 15.0, SPSS Inc., Chicago, IL, 
USA). P-values less than 0.05 were considered statistically significant. All values are 
expressed as mean ± standard deviation (SD). 
Results 
Demographic data (Table 1) and parameters commonly monitored during the cardio-
pulmonary bypass procedure (Table 2) showed no significant difference between both 
groups.  
 
Table 1: Demographics data. 
parameter group 1 (n=12) group 2 (n=11)  
age (years) 68 ± 12 66 ± 11  
body surface area (m2) 2.0 ± 0.1 1.9 ± 0.1  
gender (male /female) 11/1 10/1  
None of these variables are significantly different at the 0.05 level. 
 
Table 2. Patient related characteristics of cardio-pulmonary bypass. 
parameter group 1 (n=12) group 2 (n=11) p-value 
flow (l.min-1) 4.9±0.2 4.8±0.2 0.28 
Aps (mmHg) 92 ± 9 89 ± 8 0.46 
Apd (mmHg) 57 ± 7 58 ± 6 0.57 
Apm (mmHg)  74 ± 6 73 ± 6 0.61 
pulse pressure (mmHg) 35 ± 9 32 ± 8 0.36 
SVR (dyn.s.cm-5) 1,102 ± 91 1,077 ± 114 0.36 
Ht 0.22 ± 0.04 0.23 ± 0.03 0.46 
Aps, systolic arterial pressure; Apd, diastolic arterial pressure; Apm, mean arterial pressure; SVR, systemic 
vascular resistance; Ht, hematocrit. 
 
Figure 1 shows that the time difference (phase shift) between Qin and Qout for the 
Quadrox BEHMO 2000 oxygenator is nearly six times larger than that of the Capiox SX 
18 oxygenator (60.6 ± 35.9 ms versus 11.4 ± 8.3 ms, p=0.001). These data confirm the 
higher compliance of the Quadrox oxygenator, as measured in vitro.  
 Figure 2 shows the decline of pressure throughout the system downstream the 
pulsatile pump for both groups. Because of its higher hydraulic resistance, the Capiox 
SX18 oxygenator induced higher mean pre-oxygenator pressures (393 ± 18 mmHg 
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versus 325 ± 28 mmHg, p<0.0001). The 32% decline in mean pressure in group 1 and 
the 16% decline in group 2 both resulted in similar post-oxygenator mean pressure 
levels (269 ± 12 mmHg and 274 ± 17 mmHg, respectively, p=0.96). Noteworthy is, that 
another 73% decrease of mean pressure could be seen downstream the CPB tubing 
system, ending with comparable mean radial artery pressures in both groups (74 ± 6 
mmHg in group 1 versus 73 ± 6 mmHg in group 2, p=0.61). 
 
 
a) b)
Figure 1. Examples of flow before (Qin) and after (Qout). a - Group 1 - Capiox SX 18 oxygenator; b- Group 2 - 
Quadrox BEHMO 2000 oxygenator. The time difference between Qin and Qout (phase shift) depends from the 
compliance of oxygenator.  
 
 
Figure 2. The maximum (upper pair of lines), mean (middle pair of lines) and minimum (lower pair of lines) 
pressures before (1) and after (2) the oxygenator, and in the radial artery (3). Data expressed as mean ± SD; 
* difference between the groups, p <0.001; 
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The changes in flow energy in terms of EEP and SHE are presented in Table 3. Table 4 
shows the dynamics of pressure energy and its components. The energy necessary to 
overcome the resistance of the oxygenator was significantly higher in group 1 than in 
group 2 (5.7 ± 0.5 W.s-1 versus 4.8 ± 0.4 W.s-1, respectively, p<0.0001). The reduction in 
EEP, Wt and Ws was up to two times higher when using a Capiox oxygenator. For ex-
ample, in group 1 the Ws post-oxygenator was 33% lower than the Ws pre-oxygenator, 
whereas in group 2 these losses amounted to only 15%. In terms of SHE and Wo, how-
ever, both groups demonstrated comparable decreases (50% in group 1 versus 45% in 
group 2). 
Table 3. Energy Equivalent Pressure and Surplus Hemodynamic Energy. 
 parameter group 1 (n=12) group 2 (n=11) p-value 
before oxygenator EEP (mmHg) 527 ± 28 452 ± 28 <0.0001 
SHE (mmHg) 134 ± 12 128 ± 8 0.252 
FEE 0.34 ± 0.02 0.40 ± 0.04 0.001 
after oxygenator EEP (mmHg) 337 ± 17 342 ± 20 0.691 
SHE (mmHg) 69 ± 6 69 ± 5 1 
FEE 0.26 + 0.02 0.25 ± 0.02 0.582 
EEP, energy equivalent pressure; SHE, surplus hemodynamic energy; FEE, fractional energy excess.  
Table 4: The pressure energy and its components generated before and after oxygenators. 
 parameter group 1 (n=12) group 2 (n=11) p-value 
before oxygenator Wt (W.s-1) 5.7 ± 0.5 4.8 ± 0.4 <0.0001 
Ws (W.s-1) 4.3 ± 0.4 3.5 ± 0.3 <0.0001 
Wo (W.s-1) 1.46 ± 0.18 1.36 ± 0.12 0.207 
after oxygenator Wt (W.s-1) 3.6 ± 0.3 3.7 ± 0.3 0.649 
Ws (W.s-1) 2.9 ± 0.2 2.9 ± 0.2 0.608 
Wo (W.s-1) 0.73 ± 0.09 0.74 ± 0.07 0.820 
Wt, total pressure energy; Ws, steady component of pressure energy; Wo, oscillatory component of pressure 
energy. 
Discussion 
In the present clinical study, we evaluated the effects of two different hollow-fibre 
membrane oxygenators, in terms of pressure drop, pressure energy, energy equivalent 
pressure and surplus hemodynamic energy during normothermic CPB. Our data is in 
accordance with the notion that the position of the hollow-fibre oxygenator down-
stream of the blood pump makes the structure and hydrodynamic characteristics of 
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the membrane oxygenator critically important to the quality of pulsatile flow [14, 15, 
22]. Previous studies demonstrated that the resistance of hollow-fibre oxygenators is 
an important property that affects the quality of pulsatility [11, 14, 15, 29]. However, 
despite the fact that the pressure and total energy decline was more pronounced in 
group 1 with a high-resistance, low-compliance oxygenator, we could not confirm 
previous statements that a lower pressure drop preserves pulsatility [15,16]. The oscil-
latory energy of blood flow measured downstream both oxygenators was similar in 
terms of SHE as well as FEE. A possible explanation for this observation can be found in 
earlier studies. It has been demonstrated that less compliant oxygenators allow better 
pulsatility in comparison to more compliant oxygenators [10, 14, 15, 17]. In our study, 
the static compliance of the Quadrox oxygenator was almost four times higher than 
that of the Capiox oxygenator. Most likely, the positive effect on pulsatility of a more 
than two times lower hydraulic resistance of the Quadrox compared to the Capiox is 
overruled by the damping effect of its four times larger compliance. Thus, despite 
opposite mechanical properties (low resistance and high compliance versus high re-
sistance and low compliance), both oxygenators seem to act as comparable substantial 
buffers of oscillatory energy during pulsatile CPB. With almost 50% damping of oscilla-
tory energy by both types of oxygenator, it is difficult to disagree with the conclusion 
of Lim et al., who stated that gravity-flow hollow-fiber membrane oxygenators are 
superior for pulsatile perfusion. Such kind of oxygenators are located upstream the 
pulsatile pump and, therefore, do not dampen pulsatility [29]. 
Study limitations 
The quantification of energy actually delivered to the patient’s vascular bed requires 
recording of both flow and pressure in the aorta. In our study, however, patient he-
modynamics was assessment solely by measurement of pressure in the radial artery 
and mean pump flow. As a result, calculation of energy delivered to the patients’ vas-
cular system was not possible. Nevertheless, a loss of 50% of oscillatory energy shows 
the oxygenator to be the major element in negatively affecting the quality of pulsatile 
flow. 
Conclusion 
Despite the differences in resistance and compliance of the hollow-fibre oxygenators 
used, both oxygenators cause a comparable loss of generated oscillatory energy. Ex-
clusion of the oxygenator downstream the pulsatile pump would improve energy 
transfer during CPB.  
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CHAPTER 5 
Hydrodynamic performance and heat 
generation by centrifugal pumps 
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Abstract 
For over a century, centrifugal pumps (CP) have been used in various applications, 
from large industrial pumps to flow pumps for aquariums. However, the use of CP as 
blood pumps has a rather short history. Consequently, the hydraulic performance data 
for a blood CP are limited. The aim of our investigation was to study the hydraulic 
performance and the heat generation of three commercially available CP: Bio-Medicus 
Bio-Pump BP80 (Medtronic), Rotaflow (Jostra Medizintechnik), and DeltaStreamTM 
DP2 (MEDOS Medizintechnik AQ). 
 The study was performed using a circuit primed with a water-glycerin mixture with 
a dynamic viscosity of 0.00272 pa/s. Pressure-flow curves were obtained by a stepwise 
stagnation of the pump outlet or inlet. The temperature changes were observed using 
ThermaCAM SC2000 (Flir Systems). 
 The pumps’ performance in close to clinical conditions (‘operating region’) was 
analysed in this report. The ‘operating region’ in the case of the BP80 is positioned 
around the pressure-flow curve at a pump speed of 3000 rpm. In the case of the 
Rotaflow, the ‘operating region’ was between the pump pressure-flow curves at a 
speed of 3000 and 4000 rpm, and the DP2 was found between 7000 and 8000 rpm. 
 The standard deviation of mean pressure through the pump was used to 
characterise the stability of the pump. In experiments with outlet stagnation, the BP80 
demonstrated high negative association between flow and pressure variability (r= -
0.68, p < 0.001). In experiments with the DP2, this association was positive (r = -0.68, p 
< 0.001). All pumps demonstrated significantly higher variability of pressure in 
experiments with inlet stagnation in comparison to the experiments with outlet 
stagnation. 
 The rise of relative temperature in the inlet of a pump was closely related to the 
flow rate. The heating of fluid was more pronounced in the ‘zero-flow’ mode, 
especially in experiments with inlet stagnation.  
 In summary, (1) the ‘zero-flow’ regime, which is described in the manuals of some 
commercially available pumps, is the use of the pump outside the allowable operating 
region. It is potentially dangerous and should, therefore, never be used in clinical 
settings. (2) Using centrifugal pumps for kinetic-assisted venous return can only be 
performed safely when the negative pressure at the inlet of the pump is monitored 
continuously. The maximum allowable negative pressure has to be defined for each 
type of pump, and must be based on pump performance.  
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Introduction 
For over a century, centrifugal pumps (CP) have been used in various applications. The 
exploitation of industrial pumps is regulated by the extended set of rules and 
instructions based on the exact knowledge of the hydrodynamic characteristics of each 
specific pump. However, the use of CP as blood pumps has a rather short history. The 
majority of CP used for extracorporeal circulation (ECC) are non-metallic, volute pumps 
[1]. These pumps are preferred for ECC because they do not have a mechanical seal, 
and are considered leak proof. CP have several advantages over the roller pump. It is 
believed that they do not produce high pressures when tubing is temporarily 
obstructed or kinked, do not produce spatulated emboli from compression of the 
tubing, and cannot pump large gas emboli. However, as everywhere in nature, the 
advantages are accompanied by disadvantages. The most important disadvantages are 
that the pump has to operate inside a narrow area of pressure-flow curve, and it has a 
tendency to heat the pumped fluid [2]. The aim of our study was to evaluate the 
hydrodynamic performance and heat generation of some commercially available CP 
(Bio-Medicus Bio-Pump BP80, Medtronic, Rotaflow, Jostra Medizintechnik, and 
DeltaStreamTM DP2, MEDOS Medizintechnik AQ) in the controlled experimental 
condition. 
Materials and methods 
The study was performed using a set primed with a water-glycerin mixture with a 
dynamic viscosity of 0.00272 pa/s, which corresponds to the viscosity of blood with an 
Hct of 25% (Figure 1). The speed of each pump in the study was changed stepwise (by 
1000 rpm) from 1000 rpm to the maximum allowed by the drive console. The flow rate 
was changed in steps of 1 L/min by gradual stagnation of the pump outlet or inlet3 for 
each pump speed. After stabilisation, the flow, and inlet and outlet pressures were 
recorded by Windaq software (DtaQ Instruments, Inc). A distribution of temperature in 
the CP was observed by infrared camera (ThermaCAM SC2000, Flir Systems). The 
average relative temperatures before a pump (AR01) and at the inlet of a pump (AR02, 
eye of an impeller) were analysed for each pump in the study (Figure 2). The relative 
temperature at the base of the pump (AR03) was analysed only for the DeltaStreamTM 
DP2, because of a persistent hot area at the base of the pump, absent in other pumps 
included in the study. The average relative temperature at the AR01 was used for the 
standardisation of findings for the different pumps. All temperatures in this study are 
presented as a difference between the relative temperature at the AR01 and the AR02 
inside the pump.  
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Figure 1. The circuit diagram for centrifugal pumps evaluation. 
 
 
 
Figure 2. Infrared image of DeltaStream™ DP2. The average relative temperatures in 
marked areas were taken in analysis for each pump in the study. AR01 - the area before 
pump. AR02 - area at the inlet of the pump (eye of an impeller). AR03 - area at the 
outlet of the pump. AR04 - base of the pump. AR04 was analysed only for the 
DeltaStream™ DP2, because of persisted hot area at the base of the pump absent in 
other pumps included in the study. 
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a) 
b) 
c) 
Figure 3. The pressure-flow curves and ‘operating region’ of centrifugal pumps. a) Bio-
Medicus Bio-Pump BP80, Medtronic, b) Rotaflow, Jostra Medizintechnik, and c) 
DeltaStream™ DP2, MEDOS Medizintechnik AG. 
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The ‘operating region’ was projected on the pressure flow-curves for each pump in the 
study. The ‘operating region’ was defined by the range of pre-oxygenator pressures 
and flows. For the set used in the University Hospital Maastricht for adult patients, the 
pre-oxygenator pressure was in the range of 280 - 390 mmHg at flows from 3.9 to 5.2 
L/min. The pumps’ performance inside or close to the ‘operating region’ were analysed 
in this report. The ‘operating region’ in case of BP80 was positioned around the 
pressure-flow curve at a pump speed of 3000 rpm (Figure 3a). In the case of a 
Rotaflow, the ‘operating region’ was between the pump pressure-flow curves at 
speeds of 3000 and 4000 rpm (Figure 3b), and for DP2 it was found to be between 
7000 and 8000 rpm (Figure 3c). All data are presented as mean ± standard deviation of 
the mean. One-way ANOVA procedure was used for the comparison of mean values. 
Pearson’s correlation coefficient was used to measure an association between 
temperature changes and hydrodynamic data. A p value B/0.05 was considered to 
indicate statistical significance. 
Results 
The pressure-flow curves for each pump in the study are presented in Figure 3. The 
shut-off pressure (i.e. pressure developed by a pump at complete outlet occlusion) for 
the BP80 at 3000 rpm was 547.69 ± 12.7 mmHg. This value was significantly higher 
than the shut-off pressure for the Rotaflow at 3000 rpm (333.59 ± 1.3 mmHg, 
p<0.001), and the DP2 at a pump speed of 7000 rpm (360.89 ± 2.8 mmHg, p<0.01). In 
experiments with inlet stagnation, the BP80, at a pump speed of 3000 rpm, the inlet 
pressure decreased to -517.49 ± 8.7 mmHg. With similar conditions, the RTF and DP2 
demonstrated significantly less negative pressure at the inlet of the pump (-284.39 ± 
1.9 and 266.99 ± 109.4 mmHg, respectively, p < 0.01 in comparison to the BP80). The 
standard deviation of mean pressure through the pump was used to characterise the 
stability of the pump (Figure 4). In the case of the BP80, at a pump speed of 3000 rpm, 
the mean value of the pressure standard deviation was 3.39 ± 1.5mmHg. The Rotaflow 
had a significantly more stable flow at this condition (1.59 ± 0.4 mmHg, p < 0.001). The 
DP2 also demonstrated a lower variability of pressure at 7000 rpm, in comparison to 
the BP80 (2.39 ± 0.4 mmHg, p < 0.05). There was no statistically significant difference 
in stability of pressure between the Rotaflow and the DP2. In our experiments with 
flows higher than 4.0 L/min, the BP80 performance was relatively stable (the standard 
deviation of pressure was 2.49 ± 0.5 mmHg) and only with decreasing of flow 
(increasing of outlet stagnation) did the pump become progressively unstable (Figure 
4). Pearson’s correlation coefficient yielded a high negative association of pressure 
variability and flow for the BP80 (r = -0.68, p< 0.001). DP2 pumps also demonstrated 
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the dependence of the pump’s stability from the flow. However, this dependence was 
positive (r = 0.68, p < 0.001). If at flows < 3 L/min the average standard deviation of the 
developed pressures was 1.89 ± 0.1 mmHg, this parameter significantly rose to 2.29 ± 
0.1 mmHg (p < 0.01) at flows > 3.5 L/min, and reached 2.79 ± 0.3 mmHg at flows > 4 
L/min. In the case of the Rotaflow, we failed to determine any association of pressure 
variability and flow (r = 0.21, p > 0.05). 
 During experiments with gradual inlet stagnation, all pumps showed the same 
trends as in experiments with outlet stagnation (Figure 5). However, in these 
experiments, variability of developed pressure was significantly higher than during the 
outlet stagnation (Table 1).  
 
Table 1. Variability of pressure developed by centrifugal pumps. 
Pump 
Pressure variability (SD) mmHg 
P< 
Outlet stagnation Inlet stagnation 
BP80 at 3000 RPM 3.3±1.5 4.9±1.6 0.002 
Rotaflow 1.5±0.4 2.1±0.8 0.008 
DP2 2.3±0.4 4.6±1.6 0.0001 
 
All pumps demonstrated an increase of relative temperature at the inlet of the pump 
(Figure 6). The Rotaflow showed the highest difference in relative temperature 
between AR01 (before pump) and the AR02 (inlet of pump), 0.57 ±/0.21 °C. The mean 
differences in relative temperature in the cases of the BP80 and the DP2 were 
significantly lower (0.34 ±0.21 and 0.34 ±0.17 °C, respectively). All pumps 
demonstrated a statistically significant association between the rise of relative 
temperature at the inlet of a pump and the flow rate (BP80 R= -0.60, p < 0.01; 
Rotaflow r = -0.59, p < 0.05; DP2 r = -0.49, p < 0.05). However, only in experiments with 
the BP80 did we find an association between the rise of relative temperature and 
variability of pressure through the pump (r = 0.90,p < 0.0001). 
 In experiments with entire flow stagnation (‘zero-flow regime’), all pumps showed 
rapid rising of temperature difference in 90s on 2-4 °C (Figure 7a,b). The heating of the 
fluid was more pronounced in experiments with inlet stagnation (Figure 7b). 
 The hot area at the base of the DP2 (Figure 2) was an unexpected finding of our 
study. The relative temperature at the base of DP2 exceeded by 5.59 ± 0.1 °C the 
temperature before the pump in experiments with gradual outlet stagnation. The 
difference reached was 14.69 ± 1.2 °C in experiments with inlet stagnation. The 
temperature of this area was not related to the flow, but was highly associated with 
the pump speed (r = 0.91, p < 0.0001). 
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Figure 4. The standard deviation of pressure through the pumps with 
increasing of outlet resistance and decreasing of produced flow. 
 
 
Figure 5. The standard deviation of pressure through the pumps with 
increasing of inlet resistance and decreasing of produced flow.  
 
 
Figure 6 The difference in average of relative temperature between the AR01 
(before a pump) and the AR02 (inlet of a pump) with increasing of outlet 
resistance and decreasing of produced flow. 
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a) 
b) 
Figure 7. Average of relative temperature difference between the AR01 (before a 
pump) and the AR02(inlet of a pump) in 90” of a) outlet stagnation; b) inlet 
stagnation.  
 
Discussion 
CP were thought to be safe, harmless, and easy to operate. Apparently, this is a gross 
misconception. Several clinical studies are associating the use of CP with platelet 
destruction and hemolysis [4, 5], continuous microemboli during ECMO support [6], 
higher inflammatory response and neutrophil activation [5, 7]. The numerous materials 
dedicated to the use of industrial CP underline that operating of CP requires a great 
deal of knowledge and understanding of the hydrodynamics of pumps [2, 8]. Any CP 
has to be operated inside the so-called ‘sweet zone’. ‘Sweet zone’ is defined as an area 
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on the pump’s chart where the efficiency of the pump is highest [2]. The position and 
size of this area depends on the pump’s construction [2]. The exploitation of the pump 
outside the ‘sweet zone’ affects the pump performance. Operating the pump in the 
area to the right of the ‘sweet zone’ causes extreme turbulence and classic cavitation 
[2]. A positive association of pressure variability with flow (r = 0.68, p < 0.001), and a 
higher variability of pressure developed by the DP2 in our experiments at flows higher 
than 3.5 L/min (pump speed of 7000 rpm) could be explained by the shifting far to the 
right from the ‘sweet zone’. Our data from the same experiment with the BP80 
showed the opposite trend, with incensement of pressure variability with decreasing 
the flow rate. This fact could be explained by a shift to the left from the ‘sweet zone’. If 
the pump operates to the left from the ‘sweet zone’ it is very inefficient, with 
excessive recirculation of fluid inside the pump and cavitation [2]. The incensement of 
the internal recirculation and possible cavitation could explain the positive association 
between the temperature rise and decreasing the flow. This process is especially 
pronounced in the case of the BP80, where we also found a direct relation of 
temperature changes with variability of pressure (r = 0.90, p < 0.0001). 
 Significantly less stability of all pumps in the study, revealed in experiments with 
gradual inlet stagnation, could also be explained by the inherited quality of CP. With 
increasing the negative pressure at the inlet of pump, the situation might arise when 
pressure in the eye of the impeller falls lower than the vapor pressure of the liquid or 
saturation pressure of the gas. In this case, vaporous and gaseous cavitation can occur, 
and the capacity of the pump will be reduced [8]. The conditions when one or other CP 
starts to cavitate depend on the construction of the impeller and volute [2]. The 
minimum suction pressures higher than the vapor pressure are the pump’s minimum 
requirement curve, an obligatory part of industrial pump charts. As a general guide, 
the pressure at the suction connection of a pump has to be at least 10% higher than 
indicated at the minimum requirement curve. Some experts recommend keeping 
suction pressure 50% higher than the minimum required to avoid incipient cavitation 
[2]. If, for any reason, suction pressure falls lower than the minimally required, 
cavitation is unavoidable. The other inherited characteristic of CP, especially the CP we 
are using (volute, magnetic drive pumps), is heating up of the pumped fluid [2]. The 
heating of pumped fluid always takes place. During exploitation in a ‘sweet zone’, this 
rise in temperature is hardly noticeable, and a constant flow through the pump 
prevents over-heating. However, heat generation dramatically increases if the pump 
operates outside this zone. Additionally, at shut-off (zero-flow) regime, all power 
supplied to a CP (except for small bearing losses) goes to heating the liquid within the 
pump. The rate of the rise of the temperature depends on the amount of liquid 
contained in the casing and the power losses (shut off horsepower) of the pump. More 
pronounced warming of fluid in experiments with inlet occlusion could also be related 
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to the extensive vapor cavitation near the eye of the impeller. The collapse of bubbles 
as fluid travels from the start of the impeller vane to its tip is a high-energy exothermic 
process. Liquid microject of collapse develops pressure >1 Gpa [2,9], and the 
temperature at the point of collapse could reach 5000 K [9]. 
 We could not find an explanation for the presence of a persistent ‘hot’ area in the 
base of the DP2. 
Study limitations 
All temperatures in this study are presented as a difference between the relative 
temperature at the AR01 and AR02. The differences in thermo conductivity of 
materials at AR01 and AR02 could affect the values of the difference in relative 
temperature. However, the investigation of all pumps was carried out on the same set 
and at similar temperature regimes. Hence, the inherited error in deriving temperature 
difference(s) was the same in all experiments. That is why we believe it is correct to 
use these values in demonstrating the trends in warming the fluid by CP. 
 Our literature and experimental study demonstrated that operation of CP is not 
trouble-free and a simple process. The situation where a CP will be operated outside 
the allowable region could often appear during clinical perfusion. That is why the 
constant control of operating conditions and its comparison with a pump performance 
chart are absolutely necessary for the safe operation of CP. 
Conclusion 
(1) The ‘zero-flow’ regime, described in the manuals of some commercially available 
pumps, is the use of the pump outside the allowable operating region. It is potentially 
dangerous and should, therefore, never be used in clinical settings. 
(2) Using CP for kinetic-assisted venous return can only be performed safely when the 
negative pressure at the inlet of the pump is monitored continuously. The allowable 
negative pressure has to be defined for each type of pump and must be based on the 
pump’s performance. 
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Abstract 
Although a growing body of evidence indicates superiority of minimized 
cardiopulmonary bypass (mCPB) systems over conventional CPB systems, limited 
venous return can result in severe fluctuations of venous line pressure, which can 
result in gaseous emboli. In this study, we investigated the influence of sub-
atmospheric pressures and volume buffer capacity added to the venous line on the 
generation of gaseous emboli in the mCPB circuit. 
 Two different mCPB systems (MEC - Maquet, n=7 and ECC.O - Sorin, n=8) and a 
conventional closed cardiopulmonary bypass (cCPB) system (n=12) were clinically 
evaluated. In search for a way to increase volume buffer capacity of mCPB systems, we 
additionally evaluated the ‘Better Bladder’ (BB) in a mock circulation by simulating 
repeatedly decreased venous return while measuring pressure and gaseous embolic 
activity. 
 Arterial gaseous emboli activity during clinical perfusion with a cCPB system was 
the lowest in comparison to the mCPB systems (312 ± 465 versus 311 ± 421 with MEC 
and 1,966 ± 1,782 with ECC.O, counts per 10 minute time interval respectively, p = 
0.03). The average volume per bubble in the arterial line was the highest in cases with 
cCPB (12.5 ± 8.3 nL versus 8.0 ± 4.2 nL with MEC and 4.6 ± 4.8 nL with ECC.O, p = 0.04 
for both). Significant cross-correlation was obtained at various time offsets from 0 to 
+35 s between sub-atmospheric pressure in the venous line and gaseous emboli 
activity in both the venous and arterial line. The in vitro data showed that 
incorporation of the BB dampens fluctuations of venous line pressure by 
approximately 30% and decreases gaseous emboli by up to 85%. 
 In conclusion, fluctuations of sub-atmospheric venous line pressure during kinetic 
assisted drainage are related to gaseous emboli. Volume buffer capacity added to the 
venous line can effectively dampen pressure fluctuations resulting from abrupt 
changes in venous return and, therefore, can help to increase the safety of minimized 
cardiopulmonary bypass by reducing gaseous microemboli formation resulting from 
degassing. 
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Introduction  
A growing body of evidence indicates the superiority of minimized cardiopulmonary 
bypass (mCPB) systems compared to conventional cardiopulmonary bypass (cCPB) 
systems, regarding inflammatory reactions and transfusion requirements. Additionally, 
a more complex patient population has renewed the interest in further improvement 
of cardiopulmonary bypass (CPB) circuits in terms of reducing priming volume and 
subsequent hemodilution [1-4].  
 Evident benefits of mCPB systems, however, do not come without consequences 
[5]. In mCPB systems, the pump flow is dependent on the venous filling [6]. The equi-
librium of venous filling is a delicate one: for myocardial preservation, one needs a 
very limited venous filling (an empty right heart); on the other hand, for an acceptable 
pump flow, a certain venous filling is necessary. Moreover, venous filling is, among 
others, dependent on the position of the venous cannula and repositioning of the 
heart. So, in a mCPB system, the pump flow is directly related to the conditions of 
(reduced) venous return. During limited venous return, kinetic-assisted drainage, as 
used in these circuits, can result in severe fluctuations of venous line pressures. Some 
studies demonstrate that sub-atmospheric venous line pressures can cause large 
amounts of gaseous microemboli (GME) [7-9]. These air emboli may be sucked into the 
venous line at the site of cannulation. Also, there might be the introduction of GME to 
the circuit by degassing of blood-dissolved gasses whenever venous line pressure 
drops severely to sub-atmospheric levels. 
 Without safety mechanisms to remove or circuit modifications to handle venous 
air, gaseous emboli can easily travel through a mCPB system, causing a greater 
potential risk for continuous micro air embolization during perfusion [8, 10-14]. A 
bubble trap embedded in the venous line can decrease the amount of gross air 
entering the centrifugal pump [15-17]. Such traps are mainly intended to act as 
buoyancy. They prevent larger bubbles from entering the pump in which they can be 
milled to smaller emboli [18]. These emboli will then become suspended in the blood. 
 It is clear that every effort should be made to prevent air from being entrained in 
the venous line to decrease the risk of arterial GME. A possible way of reducing the risk 
of arterial GME is by reducing sub-atmospheric pressure peaks in the venous line. As 
described by Tamari et al., adding volume buffer capacity (i.e. ‘windkessel’) to the 
venous line by using the ‘Better Bladder’ can reduce pressure fluctuations at the inlet 
of roller or centrifugal pumps during kinetic-assisted venous drainage [19] and might, 
therefore, reduce patient embolic load and improve clinical neurological outcome. 
The aim of this study was to investigate the influence of sub-atmospheric pressures 
and volume buffer capacity added to the venous line on the generation of GME in 
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extracorporeal bypass circuits. The influence of sub-atmospheric pressure was per-
performed clinically, whereas the effect of volume buffer capacity was tested in vitro. 
Materials and methods 
Clinical 
Bubble counts and pressure data of patients who were routinely scheduled for elective 
coronary artery bypass surgery using CPB were evaluated. Perfusions were performed 
with three different CPB circuits routinely used at our institution: 
1) The first system, MEC (Figure 1), is a custom designed mCPB (Maquet 
Cardiopulmonary AG, Hirrlingen, Germany). This system consists of coated 3/8-
inch tubing (Bioline, Maquet), a centrifugal pump (Rotaflow, Maquet), and an oxy-
genator with integrated arterial filter (Quadrox-I BE-HMO71000, Maquet). 
Additionally, a hard-shell venous reservoir (VHK 2001, Maquet) is connected in 
parallel to the venous line (Figure 1), but clamped out during perfusion. In case of 
an emergency, the circuit can be converted to an open system using a vacuum 
source. The total bypass circuit requires a priming volume of approximately 800 
ml. The needle vent is attached to the venous line and cardiotomy blood is trans-
ferred to a cell saver. 
2) The Extracorporeal Circulation Optimized (ECC.O) system (Sorin Group Italia, 
Mirandola, Italy) is a mCPB phosphorylcholine-coated system (3/8-inch tubing) 
equipped with an active venous air removal device (VARD). The arterial line filter 
(Leukoguard-6, Pall, East Hills, NY, USA) is incorporated in the arterial line and a 
hard-shell venous reservoir (Dideco D970 s/v PHISIO, Sorin Group, Italy) is 
connected in parallel to the venous line (Figure 2), but clamped out during 
perfusion. As in the MEC circuit, the circuit can be converted to an open system 
using a vacuum source. The priming volume of this system is approximately 900 
ml. Separate roller pumps are used for the needle vent and cardiotomy suction, 
and blood is transferred to the cardiotomy reservoir from which it is given back to 
the circulation by occasionally opening the clamped reservoir outlet line. 
3) The conventional closed CPB (cCPB) system (Figure 3) consists of a hollow-fibre 
oxygenator (Capiox SX18, Terumo Cardiovascular Systems, Tokyo, Japan), 1/2-inch 
venous and 3/8-inch arterial line tubing, 1/2-inch medical grade silicones arterial 
pump tubing, an arterial line filter (Leukoguard-6, Pall), a collapsible venous reser-
voir (JVR 1900, Maquet), and a cardiotomy reservoir (Capiox SX hard-shell 
reservoir, Terumo). This system requires approximately 1600 ml of prime. 
Separate roller pumps are used for the needle vent and cardiotomy suction, and 
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blood is transferred to the cardiotomy reservoir from which it is given back to the 
circulation.  
 
Figure 1: Minimized cardiopulmonary bypass circuit (MEC) using a centrifugal 
pump, oxygenator with integrated arterial filter, bubble counters (BC) and 
pressure measurement near the pump inlet and in the arterial line.  
 
 
Figure 2: Minimized bypass circuit with active venous air removal device (VARD), 
oxygenator, arterial filter, bubble counters (BC) and pressure measurement near 
the pump inlet and in the arterial line. 
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Figure 3: Conventional cardiopulmonary bypass circuit with soft-shell venous reservoir, 
cardiotomy reservoir, roller pump, oxygenator, arterial filter, bubble counters (BC) and 
pressure measurement near the inlet of the venous reservoir and in the arterial line. 
 
A colloidal solution was used for system prime and normothermic perfusion was 
standardized by clinical practice. Pump flow was maintained around 2.5 L∙min∙m-2 to 
keep venous saturation in the range of 65-70%. The mean arterial pressure was kept 
around 80 mmHg using phenylephrine infusion, if necessary. 
 Microbubble activity was recorded in the venous line and in the arterial line 
downstream of the arterial filter at a sample frequency of 0.2 Hz, using a bubble 
counting device (Bubble Counter BC200, Gampt GmbH, Zappendorf, Germany). Flow 
was measured at the outlet of the oxygenator using an ultrasonic clamp-on flow probe 
(H9XL, Transonic Systems Inc., Ithaca, NY,USA). Pressures were measured in the 
venous line, approximately 80 cm from the cannula, and at the outlet of the 
oxygenator, using pressure transducers (PX604, TruWave, Edwards Lifesciences, Irvine, 
CA, USA). Electronic data were acquired with a sampling frequency of 250 Hz using a 
programmable PC-based acquisition system (MPAQ amplifier with IDEEQ software, 
Instrument Development Engineering & Evaluation, Maastricht University Medical 
Centre, Maastricht, the Netherlands).  
In vitro 
The effect of volume buffer capacity added to the venous line on the generation of 
sub-atmospheric pressure and GME was studied in a mock circulation of a mCPB circuit 
primed with 0.9% NaCl solution (Figure 4). Volume buffer capacity was provided by a 
Better Bladder (Circulatory Technology Inc., Oyster Bay, NY, USA). The centrifugal 
pump flow (Rotaflow, Maquet) was set to approximately 5 L/min with an initial 
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pressure of-80 mmHg at the inlet side of the pump (pvenous line), whereas a non-occlusive 
single-roller roller pump (20 rpm) partially, periodically and transiently obstructed the 
venous line, thereby, simulating recurring short-lasting reduced venous return as it 
may occur in clinical minimized cardiopulmonary bypass. A hollow-fibre oxygenator 
was used intermittently for the elimination of gaseous bubbles from the circulation to 
minimize re-entering using vacuum, or to restore gaseous dissolved content in the 
fluid. The effect of the Better Bladder during transient reduced venous return on 
pressure and bubble count was evaluated by respectively opening clamp A while 
closing clamp B and vice versa. 
 
 
Figure 4: Mock circulation of a minimized circuit with incorporated Better Bladder, 
pressure measurement and bubble counters (BC). The single-roller roller pump is set 
non-occlusive, and simulates repeatedly developing transient reduced venous return. 
 
Statistical analysis 
The ANOVA procedure was used to test the difference of mean values in groups. The 
relationship between venous sub-atmospheric line pressure and GME activity in both 
venous and arterial lines was analyzed by cross-correlation function and regression 
procedure (SPSS version 16.0, SPSS Inc., Chicago, IL, USA). P-values less than 0.05 were 
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considered statistically significant. All values are expressed as mean ± standard devia-
deviation. 
Results 
Clinical data 
GME activity in the arterial line during clinical perfusion with a cCPB system (n=12) was 
the lowest in comparison to the minimized systems (312 ± 465 with cCPB versus 311 ± 
421 with MEC (n=7) and 1,966 ± 1,782 with ECC.O (n=8) cumulative counts per 10 
minute time interval, respectively; p = 0.03) (Figure 5). Figure 6 shows the 
corresponding cumulative volume of gas bubbles registered in the venous and arterial 
lines per 10 min intervals. However, the average volume per bubble in the arterial line 
was highest in cases with a cCPB (12.5 ± 8.3 nL versus 8.0 ± 4.2 nL in MEC and 4.6 ± 4.8 
nL in ECC.O; p = 0.04 for both; data not graphically displayed). Overflow bubble count, 
i.e. signals coming from bubbles of more than 500 μm in diameter, were registered 
during 2 cases with MEC (28%), 2 cases with ECC.O (25%) and 3 cases with cCPB (25%). 
In all cases, the postoperative period was uneventful. 
 
 
Figure 5: Cumulative number of microbubbles registered in both venous and arterial 
lines, per cardiopulmonary bypass circuit, per 10 minute interval. 
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Figure 6: Cumulative volume of gas bubbles registered in venous and arterial lines, per 
cardiopulmonary bypass circuit, per 10 min interval. 
 
Cross-correlation function showed a significant correlation between gas bubbles and 
sub-atmospheric pressure peaks in the venous line in 56% of MEC cases, in 43% of the 
ECC.O cases, and in one case with the cCPB system (12%). In other words, the 
appearance of GME in the venous line of MEC was directly related to peaks of sub-
atmospheric pressure. In cases with cCPB using gravity drainage, GME in the venous 
line cannot be explained by ‘extreme’ suction. The bivariate correlation procedure 
showed a significant correlation between sub-atmospheric pressure peaks and GME in 
the venous line (Pearson’s correlation factor -0.35 for MEC). Much lower was this 
relationship in ECC.O cases (0.02) and in cases using the cCPB (-0.06). 
 Gas bubble activity in the arterial line was significantly related to gas bubbles in 
the venous line (Pearson’s correlation factor for MEC=0.25; ECC.O=0.65). There was no 
such correlation in cases of cCPB. 
 Table 1 shows the average venous line and venous line peak pressures during 
periods with and without emboli counts. Pump flow values in the three groups are 
comparable (Table 1). With the ECC.O system, both average venous line pressures and 
venous line peak pressures are higher than when using the MEC. 
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Table 1: Venous line pressures and corresponding pump flows. 
 without gas emboli with gas emboli p 
mean ± SD mean ± SD 
MEC n = 6,653 n = 4,211  
venous pressure peaks (mmHg) -51±38 -81±60 0.0001 
venous pressure (mmHg) -44±33 -66±48 0.0001 
flow (L/min) 4.0±1.4 3.9±1.2 0.0001 
 
ECC.O n = 6,977 n = 3,104  
venous pressure peaks (mmHg) -23±46 -37±48 0.0001 
venous pressure (mmHg) -19±42 -29±42 0.0001 
flow (L/min) 4.1±1.4 4.3±1.0 0.0001 
 
cCPB system n = 1,362 n = 5,247  
venous pressure peaks (mmHg) 28±20 23±12 0.0001 
venous pressure (mmHg) 38±19 35±10 0.0001 
flow (l/min) 3.9±1.4 4.2±0.9 0.0001 
MEC, minimized cardiopulmonary bypass; ECC.O, extra corporeal circulation optimized; cCPB, conventional 
closed cardiopulmonary bypass; SD, standard deviation. 
In vitro data 
The incorporation of the BB can dampen fluctuations of the venous line pressure 
during transient conditions of reduced venous return in mCPB by approximately 30%. 
Figure 7 shows the effect of the Better Bladder during limited venous return on venous 
line pressure and gaseous emboli measured in the mock circulation. By dampening, the 
Better Bladder decreased the number of GME by up to 85%. 
 
 
Figure 7: Venous pressure and resultant bubble count during conditions of reduced 
venous return with (BB) and without (no BB) Better Bladder inline the minimized 
bypass circuit. With the Better Bladder included, venous pressure is higher and bubble 
count is clearly diminished. 
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Discussion 
This study investigated the influence of sub-atmospheric pressures and added volume 
buffer capacity on the generation of gaseous microemboli (GME) in minimized 
cardiopulmonary bypass (mCPB) systems. Lower sub-atmospheric pressures tend to 
induce higher amounts of GME, whereas volume buffer capacity added to the venous 
line dampens fluctuations of venous line pressure and reduces GME generation. 
 The use of cardiopulmonary bypass (CPB) may result in the introduction of 
gaseous emboli into the patient's arterial circulation. These may be introduced during 
drug infusion via the central venous lines of the anaesthesia or via infusion into the 
CPB circuit itself [20, 21]. Although decreasing venous line pressure increases the risk 
of air aspiration at the cannulation site, to the best of our knowledge, there is no 
clinical data available correlating data on GME occurrence with low venous line 
pressure and degassing in CPB systems. According to Henry’s Law, a sudden decrease 
of line pressure results in gaseous bubble formation in the blood [22], as a pressure 
decrease disturbs the dissolved gas equilibrium. This study discusses the often 
underestimated, or even unknown, but present risk of bubble formation when blood is 
exposed to sub-atmospheric pressures. 
 The venous line pressures measured in the MEC group were significantly lower 
than to those in the ECC.O group (Table 1). This is due to the fact that the circuit and, 
in our cases, the pressure measurement site is located lower in relation to the 
patient’s position when compared to the MEC system, where it is located nearly at 
table height. The positive pressure measured in the cCPB group can be explained by 
the hydrostatic column pushing on the sensor located in the venous line near the 
reservoir inlet. In the ECC.O group, arterial GME count and volume were higher than in 
the MEC and cCPB group. This can be explained by the fact that both the ECC.O and 
cCPB use cardiotomy suction, which can introduce bubbles into the circuit, but the 
cCPB features a collapsible venous reservoir that can collect bubbles. In contrast, the 
average arterial bubble volume was highest in the cCPB group, which can be explained 
by the absence of a centrifugal pump that can mill air emboli into smaller bubbles. 
Moreover, GME resulting from degassing are expected to be smaller, which is seen in 
the MEC and ECC.O groups. 
 GME can be quantified using bubble counting devices, commercially available for 
clinical application. Two common devices used are the GAMT BCC200 and the Emboli 
Detection and Classification quantifier (Luna Innovations, Roanoke, VA, USA) [23]. Both 
devices, however, show major limitations when used for studying ‘worst-case’ 
scenarios. A worst-case scenario can be a situation of embolic showers or macro air 
emboli conditions in which the bubble counters cannot discriminate between 
individual bubbles (bubble count overflow). Threshold levels, however, can vary 
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between devices and results obtained by one device in a first study cannot be com-
compared or exchanged with results from another device in a second study [24]. 
Therefore, great care should be taken when correlating measured data with 
neurocognitive outcome. 
 As mentioned before, mCPB systems have an increased risk of air entrainment 
[25, 26]. The data in this study suggest that there is also the risk of introducing GME, 
even if venous blood is GME free. GME might come from degassing and could add to 
the explanation that some studies fail to translate the salutary effects of mCPB into 
clinical benefit [5, 27]. 
 Bubbles found in the arterial line can have their origin in the venous line when 
entering the circuit at the cannulation site. With mCPB systems, some surgeons, there-
fore, suggest using a double purge-string suture to prevent any air from being sucked 
into the circulation. This double snaring, however, cannot prevent the induction of 
GME resulting from degassing. The degassing occurs in the venous line and inside the 
centrifugal pump during conditions of reduced venous return. With extreme blood 
loss, luxation of the heart, cannula obstruction or tube kinking, pump flow is drastically 
diminished and venous line pressure can transiently peak down to -300 mmHg or even 
less. Like Tamari et al., we also noticed the Better Bladder dampened pressure 
fluctuations (Figure 7) [19]. In addition to the reduction of sub-atmospheric peak 
pressures, we found a decrease in GME formation. Nevertheless, the Better Bladder 
remains a passive device that adds volume buffer capacity to the venous line. It does 
not solve the underlying mismatch of venous return and pump flow. Pump control 
using servo-regulation and improved venous cannula design has been proposed to 
optimize venous drainage [28-30]. Minimized CPB systems with Better Bladder and 
pump servo-regulation, combined with anti-obstructive venous cannula design, could 
prevent venous line pressures from peaking down to excessively low levels with 
concomitant GME formation, while pump speed adapts to venous drainage to 
maintain the maximal level of support available at that instance. 
 In conclusion, severe sub-atmospheric fluctuations of venous line pressure during 
kinetic-assisted drainage, as used in minimized cardiopulmonary bypass systems, are 
related to gaseous microemboli. Volume buffer capacity added to the venous line can 
effectively dampen pressure fluctuations resulting from abrupt changes in venous 
return and, therefore, can help to increase the safety of minimized cardiopulmonary 
bypass by reducing gaseous microemboli formation resulting from degassing. 
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CHAPTER 7 
General discussion 
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This dissertation outlines the boundaries that illustrate the growth of extracorporeal 
life support and acknowledge frontier areas where the expertise of the clinical 
perfusionist is required. Because of its dual nature the nucleus of knowledge in 
extracorporeal technology is a synthesis of several branches of physical sciences as 
well as life sciences. For that, this dissertation includes examples of investigation of 
both sides of heart-lung machine - patient system. 
 
Clinical studies in extracorporeal life support technology inherit not only the broad 
spectrum of investigation methods, but also difficulties of any clinical research. 
However, scientists in extracorporeal life support technology have to deal with specific 
obstacles, due to unique interaction between patient’s body and heart-lung machine. 
The first obstacle in extracorporeal life support research is the selection of reference 
values or ‘normal ranges’. Normal ranges have traditionally been defined on the basis 
of measurements of the “analyte” in question in a sufficiently large sample of 
individuals from an appropriate healthy population, in terms of age, sex, ethnicity, and 
other determinants [1]. Thus, perfunctory transfer of human physiology knowledge 
and reference values to the extracorporeal life support is erroneous simply because of 
mismatch of determinants. 
 Another obstacle is the choice of outcome measures. The choice of outcome 
measures is one of the most important considerations in designing clinical 
investigations [2]. It is recognized that clinical endpoints are the most credible 
characteristics used in medical studies [2, 3] and are the preferable outcome measures 
of any clinical study. In cardiovascular trials the events like death, cardiovascular 
death, myocardial infarction, stroke, and heart failure are natural clinical endpoints [4, 
5]. However, multiple pathogenesis as well as multiple etiological nature of these 
complications create additional research obstacles and even can lead to a misleading 
conclusions. 
 
In the study entitled "Neurological complications after coronary artery bypass grafting 
related to the performance of cardiopulmonary bypass" (chapter 2), the above named 
difficulties in clinical studies of extracorporeal life support were addressed. The 
postoperative neurological complications with clinical manifestations were chosen as 
an outcome measure. In other words, we sought to search for factors that solitary or in 
combination can be related to the early postoperative neurological disorders after an 
apparently normal procedure. This, as well as, understanding of the heart-lung 
machine-patient system as a complex of dynamically alternating relations mainly 
determines the method of the study. Electronic data recorded during surgery allowed 
to include the changes of perfusion parameters, such as pressure and flow into the 
analysis. Interestingly, we, as well as authors of early [6, 7] and more recent [8, 9] 
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published studies, could not find the ‘optimum’ arterial pressure. However, defining 
natural groups (clusters) in the population and including the variability of perfusion 
parameters in the analysis made it possible to demonstrate that even apparently 
normal cardiopulmonary bypass (CPB) procedures affect the impact of common clinical 
risk factors on postoperative neurologic complications. Particularly, patients who 
underwent CPB procedures with large fluctuations in hemodynamic parameters 
showed an increased risk for the development of postoperative neurologic 
complications. 
 Despite the clear superiority of clinical endpoints as outcome measures, it is 
recognized that in many investigations the expected rate of clinical endpoints is low, 
resulting in the need for a large sample size and longitudinal follow-up to obtain 
adequate statistical power [5]. An alternative approach is to use indirect measures, 
such as biomarkers that include physical signs of disease, laboratory measures, and 
radiological tests, as replacement of endpoints or 'surrogates' for clinically meaningful 
endpoints [2, 3, 10]. 
 
In extracorporeal life support studies, the use of surrogate endpoints is even more 
complicated by the absence of reference ranges for the most of adopted parameters 
of CPB. 
 One of the possible ways to get around the absence of reference ranges is used in 
the study presented in chapter 3 (The oxygen debt during routine cardiac surgery: 
illusion or reality?) of this dissertation. The aim of the study was to determine the 
existence and causes of oxygen debt during cardiac surgery. The challenge in study 
design was the absence of established values for critical oxygen delivery (DO2crit) during 
the CPB procedure, i.e. for the heart-lung machine - patient system. Furthermore, it is 
recognized that the value of DO2crit varies for different organs, clinical conditions, and 
pathologies [11]. Thus, it is doubtful that an universal ‘good for all’ DO2crit value can be 
established. The direct way of determining DO2crit and presence of oxygen debt is 
measurement of lactate and pyruvate concentration (as a biochemical substrate of 
anaerobic metabolism). In our study, plasma lactate and pyruvate levels did not 
exceed physiological ranges at rest in any patient at any study time point. In other 
words, using this method we failed to define the DO2crit value and uncover the oxygen 
debt during CPB in our patient population. 
 Another way of locating DO2crit in individual patients is to compare patients’ actual 
oxygen consumption (VO2) with their expected oxygen consumption corrected to the 
actual patient condition (body temperature, exclusion of heart and expends at 
breathing). However, this method also did not show lack of oxygen delivery during 
surgery and in the early postoperative period. Interestingly, by using the latter 
approach we revealed another than the ‘oxygen debt repayment’ explanation of 
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‘biphasic response’ of reduced oxygen consumption during surgery followed by an 
increase of VO2 in our group of patients. A plot of actual oxygen consumption against 
the sample points (Figure 3 in Chapter 3) shows a ‘biphasic response’. However, simple 
exposure of changes of body temperature and related expected oxygen consumption 
showed exactly the same ‘biphasic’ pattern. Thus, it is most likely that the ‘biphasic 
response’ is related to active cooling during CPB followed by re-warming and 
postoperative hyperthermia. 
 Our interest in DO2crit and VO2 as study endpoints was raised by multivariate 
nature of these parameters. The oxygen delivery as well as oxygen consumption 
represents a composite physiological function with interaction of several lower order 
physiological processes. These parameters can give more generalized characteristic of 
extracorporeal life support than hemoglobin concentration, blood flow, and oxygen 
content, separately. Replacing of simple, single parameters by more complex ones is 
becoming more popular, e.g. slowly developing changes in understanding the role of 
hemoglobin and/or hematocrit level in taking clinical decisions [12-15]. 
 As a general conclusion of this part of the discussion, the opinion is confirmed of 
those who state that despite many advances, definitive answers and consensus on 
optimal practices are not realized and fundamental questions regarding the 
management of CPB remain unanswered [9, 16]. However, it is clear that key 
attributes of optimal practice regarding management of extracorporeal life support is 
the careful, forthcoming balance between individual patient requirements (e.g. 
expected and actual oxygen consumption) and limitations in possibilities to satisfy 
these requirements (flow and gas exchange limitations, dilution, surgery necessities, 
etc.). 
 
Presence of an artificial part in the patient-heart-lung machine system (heart-lung 
machine and its ‘physiological block’) raises more questions and problems, specific to 
the extracorporeal technology. There are numerous examples of such joint problems, 
i.e. blood-surface contact activation, systemic inflammatory response, hemolysis, 
anticoagulation, inhibition of fibrinolysis, microemboli and alteration of rheological 
characteristics of blood. Solution of these problems requires not only knowledge in 
respective scientific fields, but also creation of new or adaptation of previously 
developed methods of investigation. For instance, one of the problems and everlasting 
discussion can be formulated by rephrasing William Shakespeare: “to pulse, or not to 
pulse, that is the question”. The discussion about usefulness and necessity of pulsatile 
flow during CPB has continued for more than half a century [17]. Noteworthy in this 
discussion is the fact that pulsatile CPB in clinical trials is most often characterized only 
by the heart-lung machine settings or by arterial pulse pressure, and not by objective 
quantitative measures. Lack of precise quantification of pressure and flow waveforms 
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is recognized as one of the reasons for the controversy in research dealing with pulsa-
pulsatile CPB [18-23]. Chapter 4 (The effect of oxygenator mechanical characteristics 
on energy transfer during clinical cardiopulmonary bypass) addresses this latter issue, 
using direct calculations of pressure energy (steady and oscillatory components) and 
related parameters (Shepard’s energy equivalent pressure and surplus hemodynamic 
energy). These calculations allowed to precisely quantify different levels of pulsatility 
and energy loss through the oxygenator. Despite the difference in resistance of the 
evaluated oxygenators, a similar energy drop (≈50%) was observed. It is likely that 
further progress in search for answers in regards to necessity and feasibility of pulsatile 
perfusion is not only in usage of precise quantitative tags, but also in excluding the 
oxygenator downstream of the pulsatile device and reducing the length of the arterial 
line, thus integrating the circuit as much as possible. 
 
 
Figure 1. Best efficiency point and allowable operating region (‘sweet zone’) 1. 
 
Another critical part of patient-heart-lung machine system is the pump. There are two 
types of pumps (roller and centrifugal) independently or in combination used for CPB. 
 
                                                                
1  
Best Efficiency Point (BEP) is the rate of flow and pressure at which the pump is most efficient. The area 
within 80 -110% of BEP is an allowable operating region (‘sweet zone’) where the pump performance is 
optimum or close to optimum. The pump, which is operating in the zone far to the right from BEP causes 
extreme turbulence and classic cavitation. On the other hand, if the pump is operated far to the left from 
BEP, it is very inefficient with excessive recirculation of fluid inside the pump and cavitation. This low flow 
and high pressure condition causes the fluid to overheat. [Bachus, L., Custodio, A., Know and Understand 
Centrifugal Pumps. 2003, Oxford: Elsvier]. 
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Nowadays, with development of minimized systems for CPB, usage of centrifugal 
pumps for routine procedures is significantly increased. Centrifugal pumps have 
several advantages over the roller pumps. It is believed that centrifugal pumps do not 
produce high pressures when tubing is temporarily obstructed or kinked, do not 
produce spatulated emboli from tubing compression, and cannot pump large gas 
emboli. Decades of usage of centrifugal pumps in combination with an open system, 
created a false feeling of their absolute safety and universal applicability. However, as 
everywhere in nature, advantages are accompanied by disadvantages. The most 
important but rarely realized limitations of centrifugal pumps are the narrow area of 
pressure-flow curve wherein the pump has to operate and its tendency to heat the 
pumped fluid [24]. The main goal of the study outlined in chapter 5 (Hydrodynamic 
performance and heat generation by centrifugal pumps) was to broaden the 
knowledge of concepts in regards to ‘best efficiency point’ and ‘allowance region’, or 
so-called ‘sweet zone’ (Figure 1).  
 Most likely that the low awareness in limitations of centrifugal pumps and their 
exploitation outside ‘allowance region’ is a cause of deleterious effects reported in the 
literature. Several clinical studies are associating the use of centrifugal pumps (in close 
systems) with platelet destruction and haemolysis [25-28], continuous micro-
emboli[29, 30], higher inflammatory response and neutrophil activation [26, 31, 32]. 
 Evaluation of pressure variability at diverse flow rates showed different patterns 
for studied pumps. The possible mechanism of pressure variability incensement is 
changes of flow patterns inside the pump with moving exploitation conditions to the 
left or right from the ‘allowance region’. Suggested mechanism of pressure instability 
found conformation in the study by Day et al [33]. The authors reported alterations of 
flow pattern at both high and low flow rate conditions with appearing regions of 
elevated shear stress adjacent to separated or stagnant flow. In addition, dependency 
of power spectral density of the motor current waveform from pre- and post-load of 
ventricular assist devices was reported [34]. It is possible that monitoring of pressure 
variability could help in timely diagnostic of deviation and exploitation conditions 
outside the ‘allowance region’. Another finding of the study presented in chapter 5, 
which has noteworthy clinical implications, is the significantly less stability of all pumps 
in experiments with gradual inlet stagnation. Increasing of the negative pressure at the 
pump inlet could lead to a situation where pressure in the eye of the impeller falls 
lower than the vapor pressure of the liquid or saturation pressure of the gas [35]. We 
even observed appearance of persistent gaseous microemboli downstream of the 
pump in these experiments [36]. Continuous monitoring of pressure at the inlet of the 
centrifugal pump is therefore essential for safe operating within a closed system. 
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The idea of safety in exploitation of centrifugal pumps received further development in 
research presented in chapter 6 (Can minimized cardiopulmonary bypass systems be 
safer?) of this dissertation. 
 Development of new, smaller systems for extracorporeal life support during 
cardiac surgical interventions boosted a fountain of publications, in which the benefits 
of these systems thrust out by emphasizing one or two biomarkers. The hazard of such 
approach is the uncritical use of surrogate endpoints, which in history caused the 
needless deaths of thousands of patients [37, 38, 39]. The overenthusiasm around 
miniaturized systems can lead to another well-known source of bias, i.e. the selective 
reporting of positive and 'statistically significant' results [40]. All these create a 
situation in which the dangers of miniaturized systems are easily forgotten. In this 
unhealthy, excited atmosphere only few authors warn about hazards and loss of safety 
margins inherent to miniaturized systems [30, 41-44]. During limited venous return, 
kinetic-assisted drainage as used in these circuits can result in severe fluctuations of 
venous line pressures and consequently large amounts of gaseous microemboli. 
Without safety mechanisms to remove or circuit modification to handle venous air, 
gaseous emboli can easily travel through a minimized CPB system, causing a greater 
potential risk for continuous micro air embolization during perfusion. Results of our 
study are in accordance with previously reported low resistance of minimized systems 
to gas emboli. Gaseous emboli activity in the arterial line during clinical perfusion with 
a conventional CPB system was the lowest in comparison to the minimized CPB 
systems (Figure 5 in Chapter 6). Notable, in cases with minimized systems significant 
cross-correlation was obtained at various time offsets from 0 to 35 seconds between 
sub-atmospheric pressure in the venous line and gaseous emboli activity in both the 
venous and arterial line. It is clear that decreasing of pressure fluctuations in the 
venous line using miniaturized systems is one of the key elements in prevention of 
gaseous microemboli. Incorporation of a volume buffer capacity device in the venous 
line facilitates damping of sub-atmospheric pressure fluctuation by approximately 30% 
in experimental and clinical settings. Moreover, a decrease in the amount of gaseous 
emboli up to 85% was observed in vitro. Adding a volume buffer capacity in the venous 
line is an essential circuit modification, which increases stability of the CPB procedure 
and gas microemboli load feature for these systems. 
 
In summary, the main subject of this interdisciplinary science can be defined as an 
integral heart-lung machine - patient system with unique, specific relations and 
reference values. Herewith optimal practice in management of extracorporeal life 
support is the careful, forthcoming balance between individual patient’s requirements 
and limitations (flow and gas exchange limitations, dilution, surgery necessities, etc.). 
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This statement includes two keystones of optimal practice in extracorporeal life sup-
support:  
• individual approach which can be formulated as “each patient is unique, each 
extracorporeal life support procedure must answer to dynamic changes and 
necessities of patient’s homeostasis”; 
•  the perfusionist must find acceptable balance between patient’s requirements on 
the one hand and limitations during surgery, intensive therapy and resuscitation 
on the other hand. 
With the recent success of application of extracorporeal life support in intensive 
therapy (H1N1 pandemic), it increasingly attracts attention and gains a more 
significant position in everyday clinical practice. It is very difficult to foresee how close 
the presented description to real structure of emerging science is, but in any case it is 
of the utmost importance that it is carefully preserved and passed on to the coming 
generation of the perfusion profession. 
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Summary 
After two centuries of dormant development and relatively recent association with 
cardiac surgery followed by explosive technological progress, extracorporeal life 
support (ELS) has made a quantum leap especially during the last two decades. 
Scientific and technological progress in related areas, facilitate deepening and 
intensification of traditional as well as new methods and technics of ELS. Expanding 
areas of application and increasing accumulation of experience and knowledge, 
creates the necessity of formalizing of knowledge, thus giving birth to extracorporeal 
life technology as science. 
 The nucleus of knowledge in extracorporeal technology, because of its dual 
nature, is a synthesis of several branches of physical sciences as well as life sciences. As 
any science at the early stages of development, extracorporeal technology is re-using 
investigation methods of predecessors. With these, it inherits all difficulties of clinical 
studies and also brings in specific snags. First is the selection of reference values or 
‘normal ranges’. Coupling to a heart-lung machine simply disrupts or changes most of 
the mechanisms of homeostasis. Thus, perfunctory transfer human physiology 
knowledge and reference values to extracorporeal life support conditions are a 
dangerous mistake. 
 Another hitch, typical for all medical investigations, but much more pronounced in 
extracorporeal technologies studies is the choice of outcome measures. It is 
recognized that clinical endpoints are most credible in medical studies and are the 
preferable outcome measures of any clinical study. However, the multiple etiological 
nature of postoperative complications create additional research obstacles that can 
lead to misleading conclusions. Chapter 2 of this manuscript is an attempt to ‘see the 
wood for the trees’, and to bypass these obstacles. Defining natural groups (clusters) in 
a population of 1300 cases, made it possible to demonstrate that some patients with 
large fluctuations in hemodynamics during cardiopulmonary bypass procedure are at 
risk for the development of postoperative neurologic complications. 
 Despite the clear superiority of clinical endpoints as outcome measures, in many 
investigations the margins between various clinical endpoints is low, resulting in the 
need for a large sample size and longitudinal follow-up to obtain adequate statistical 
power. An alternative approach is to use indirect measures, such as biomarkers, as 
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replacement of endpoints, so called 'surrogates' of clinically meaningful endpoints. 
Selecting and validating proper parameters as surrogates is subject of numerous 
medical studies. However, in extracorporeal life support studies, the selection of 
surrogate endpoints is even more complicated because of the absence of reference 
ranges for most of the adopted parameters of cardiopulmonary bypass. Chapter 3 of 
this manuscript is a demonstration of the use of individual expected oxygen 
consumption rates corrected to the actual patient condition as reference value for the 
assessment of actual oxygen consumption. This individualized approach showed that 
apparent ‘dependence’ of average oxygen consumption from average oxygen delivery 
is just an illusion and that modern cardiopulmonary bypass procedures are not 
associated with oxygen debt accumulation.  
 The presence of an artificial part in the patient-heart-lung machine system (the 
physical and ‘physiological block’) raises more problems, specific to extracorporeal 
technology. Solving these problems requires knowledge of physics and adaptation of 
previously developed methods of investigation in this area. Chapters 4 and 5 are 
examples of using methods and criteria of ‘physical’ sciences for investigations in 
extracorporeal life support technology. Furthermore, results of centrifugal pump 
evaluation (chapter 5) emphasize the necessity of related technological knowledge for 
safe exploitation of the heart-lung machine (centrifugal pumps as a part of the device). 
The issue of safety in using centrifugal pumps was further developed in chapter 6. The 
invention and introduction in clinical practice allowing miniaturization of 
extracorporeal systems, is at least, in some situations, beneficial. However, the 
overenthusiasm around miniaturized systems creates a situation in which the dangers 
of these systems are easily forgotten. In case of limited venous return, kinetic-assisted 
drainage as used in these circuits can result in severe fluctuations of venous line 
pressures and consequently large amounts of gaseous microemboli. Without safety 
mechanisms or circuit modifications to handle venous air, gaseous emboli can easily 
travel through a minimized cardiopulmonary bypass system, causing a greater 
potential risk for continuous micro air embolization during perfusion. We 
demonstrated that incorporation of a volume buffer capacity device in the venous line 
facilitates damping of sub-atmospheric pressure fluctuation and decreases the gas 
microemboly load in experimental and clinical settings. 
 In summary, the main subject objective for extracorporeal life support technology 
as interdisciplinary science in itself, can be defined as the study of the integral heart-
lung machine - patient system with its unique and specific relations and reference 
values. Optimal practice in management of extracorporeal life support is the careful, 
balance between individual patient’s requirements and procedural limitations (flow 
and gas exchange limitations, dilution, surgery necessities, etc). This statement 
includes two keystones for best practice in extracorporeal life support:  
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• individual approach which can be formulated as “each patient is unique, each 
extracorporeal life support procedure must answer to dynamic changes and 
necessities of patient’s homeostasis”; 
• the perfusionist must find acceptable balance between patient’s requirements on 
the one hand and limitations during surgery, intensive therapy and resuscitation 
on the other hand. 
 
It is very difficult to foresee how close the presented description is to a real emerging 
science, but it is in any case of the utmost importance that the keystones of best 
practice in extracorporeal life support are carefully preserved and passed on to the 
coming generation of the perfusionist. 
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Samenvatting 
Nadat de ontwikkeling twee eeuwen heeft stilgelegen en er pas relatief recent een 
relatie met de hartchirurgie is ontstaan, die is gevolgd door een explosieve 
technologische voortuitgang, heeft de extracorporeal life support (ELS) met name 
gedurende de afgelopen twintig jaar een reusachtige stap voorwaarts gemaakt. 
Wetenschappelijke en technologische vooruitgang op gerelateerde terreinen hebben 
een verdieping en verbetering van zowel traditionele als nieuwe methoden en 
technieken van ELS mogelijk gemaakt. Uitbreiding van de toepassingsgebieden en de 
toename van de ervaring en de kennis maken het noodzakelijk om deze kennis te 
formaliseren, waarmee de technologie van extracorporeal life support een wetenschap 
is geworden. 
 De kern van de kennis omtrent de extracorporele technologie is, gezien de duale 
aard daarvan, een synthese van verschillende takken van zowel de fysische 
wetenschappen als de levenswetenschappen. Zoals elke tak van wetenschap in de 
vroege fase van zijn ontwikkeling maakt de extracorporele technologie gebruik van de 
onderzoeksmethoden die reeds eerder zijn toegepast door zijn voorgangers. Hiermee 
komen alle problemen van klinische studies naar voren, terwijl er ook specifieke 
obstakels worden geïntroduceerd. De eerste hiervan is de selectie van de 
referentiewaarden of "normaalwaarden". Wanneer een mens aan een 
hartlongmachine wordt aangesloten worden de meeste mechanismen die zorgen voor 
de homeostase verstoord of veranderd. Het is daarom een gevaarlijke fout om 
routinematig de kennis omtrent de fysiologie van de mens en de referentiewaarden 
toe te passen onder omstandigheden van extracorporeal life support. 
 Een ander probleem, dat typisch is voor elk onderzoek op medisch gebied maar 
dat meer uitgesproken is in het geval van onderzoek op het gebied van extracorporele 
technologieën, is de keuze van de uitkomstmaten. Het is algemeen aanvaard dat bij 
medisch onderzoek klinische eindpunten het meest geloofwaardig zijn en dat dit de 
uitkomstmaten zijn waaraan tijdens ieder klinisch onderzoek de voorkeur aan wordt 
gegeven. Het feit dat postoperatieve complicaties multiple etiologieën hebben 
veroorzaakt extra obstakels voor het klinische onderzoek, waardoor de conclusies 
misleidend kunnen zijn. In hoofdstuk 2 van dit manuscript wordt een poging gedaan 
om "door de bomen het bos te zien" en deze obstakels te omzeilen. Door het 
definiëren van natuurlijke groepen (clusters) binnen een populatie van 1.300 patiënten 
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is het mogelijk geworden aan te tonen dat sommige patiënten, bij wie tijdens een 
cardiopulmonary bypass-procedure grote fluctuaties in de hemodynamiek optreden, 
een risico lopen om postoperatief neurologische complicaties te ontwikkelen.  
 Ondanks de duidelijke superioriteit van klinische eindpunten als uitkomstmaten 
zijn tijdens veel onderzoeken de verschillen tussen de diverse klinische eindpunten 
gering, waardoor het noodzakelijk is om een grote onderzoekspopulatie te hebben en 
een longitudinale follow-up uit te voeren om statistisch adequaat verschillen te 
kunnen aantonen. Een alternatieve benadering is het gebruikmaken van indirecte 
uitkomstmaten, zoals biomarkers, in plaats van klinische eindpunten; dit zijn de 
zogenaamde "surrogaten" voor eindpunten die klinisch van belang zijn. Het selecteren 
en valideren van de juiste parameters als surrogaten is het onderwerp van vele 
medische onderzoeken. Bij het onderzoek naar extracorporeal life support is de 
selectie van surrogaat-eindpunten nog gecompliceerder omdat voor de meeste 
parameters die worden toegepast tijdens cardiopulmonary bypass geen 
referentiewaarden bestaan. In hoofdstuk 3 van dit manuscript wordt het gebruik 
beschreven van de individuele, verwachte zuurstofconsumptie, die wordt gecorrigeerd 
voor de feitelijke toestand van de patiënt, als referentiewaarde voor het feitelijke 
zuurstofverbruik. Deze geïndividualiseerde benadering laat zien dat de schijnbare 
"afhankelijkheid" van de gemiddelde zuurstofconsumptie van de gemiddelde 
zuurstofvoorziening een illusie is en dat moderne cardiopulmonary bypass-procedures 
niet gepaard gaan met het ontstaan van een zuurstoftekort.  
 De aanwezigheid van een kunstmatig onderdeel in het systeem van patiënt-en-
hartlongmachine (het fysische en "fysiologische blok") veroorzaakt meer problemen, 
die specifiek zijn voor de extracorporele technologie. Om deze problemen te kunnen 
oplossen is kennis van de fysica vereist en moeten eerder ontwikkelde methoden voor 
onderzoek op dit gebied worden aangepast. In hoofdstuk 4 en hoofdstuk 5 worden 
voorbeelden gegeven van het gebruik van methoden en criteria uit de fysische 
wetenschappen bij het onderzoek naar de technologie van extracorporeal life support. 
Bovendien maken de resultaten van onderzoek naar centrifugaalpompen (hoofdstuk 5) 
duidelijk dat voor een veilig gebruik van de hartlongmachine (waarvan een 
centrifugaalpomp een onderdeel is) technologische kennis op dit gebied noodzakelijk 
is. Het onderwerp van de veiligheid bij het gebruik van centrifugaalpompen komt 
nader aan de orde in hoofdstuk 6. De ontwikkeling en introductie in de klinische 
praktijk van geminiaturiseerde systemen voor extracorporele circulatie biedt, 
tenminste in een aantal omstandigheden, voordelen. Het overmatige enthousiasme 
voor geminiaturiseerde systemen creeërt echter een situatie waarin de gevaren van 
deze systemen gemakkelijk worden vergeten. In het geval van een beperkte veneuze 
terugvloed kan de actieve drainage zoals die in dergelijke circuits wordt toegepast 
leiden tot grote schommelingen van de druk in de veneuze lijn en daarmee tot de 
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vorming van grote hoeveelheden gasvormige microembolieën. Zonder veiligheidsme-
veiligheidsmechanismen of aanpassingen aan het circuit om lucht in het veneuze 
systeem te verwerken kunnen gasvormige embolieën gemakkelijk een 
geminimaliseerd systeem voor cardiopulmonary bypass passeren, met als gevolg een 
toename van het risico voor continue embolisatie van microscopische luchtbelletjes 
tijdens de perfusie. Wij hebben aangetoond dat het inbouwen van een apparaat voor 
volumebuffering in de veneuze lijn het dempen van de subatmosferische 
drukfluctuaties vereenvoudigt en zowel onder experimentele omstandigheden als in 
klinische situaties leidt tot een afname van de hoeveelheid gasvormige 
microembolieën. 
 Samengevat kan het belangrijkste doel van de extracorporeal life support-
technologie als zelfstandige interdisciplinaire wetenschap worden gedefinieerd als het 
bestuderen van het integrale systeem van hartlongmachine plus patiënt met zijn 
unieke en specifieke relaties en referentiewaarden. Het optimale management van de 
extracorporeal life support vereist het handhaven van een zorgvuldige balans tussen 
de behoeften van de individuele patiënt en de beperkingen van de procedure 
(beperkingen in de stroom en uitwisseling van gassen, verdunning, eisen die 
samenhangen met de chirurgische procedure). Deze stelling omvat twee kernpunten 
van de "best practice" in extracorporeal life support: 
• een individuele benadering, die kan worden worden omschreven als: elke patiënt 
is uniek, en elke extracorporeal life support-procedure moet rekening houden met 
dynamische veranderingen en de eisen die worden gesteld door de homeostase 
van de patiënt; 
• de perfusionist moet een acceptabel evenwicht vinden tussen enerzijds de 
vereisten van de patiënt en anderzijds de beperkingen van de chirurgische 
procedure, de intensieve behandeling en een reanimatie. 
 
Het is bijzonder moeilijk om te voorspellen hoe dicht de gegeven beschrijving bij een 
echte, zich ontwikkelende wetenschap ligt, maar het is in elk geval van het grootste 
belang dat het fundament van de "best practice" in extracorporeal life support 
zorgvuldig bewaard blijft en wordt overgedragen op de volgende generaties 
perfusionisten.  
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Резюме 
 
Після двох століть прихованого розвитку і відносно недавнього поєднання з 
сердцевосудинною хірургією та подальшого вибухового технічного прогресу, 
екстракорпоральна підтримка життя, особливо протягом останніх двох десятиліть, 
перетерпіла значні якісні зміни. Науково-технічний прогрес в суміжних галузях, 
сприяли поглибленню та інтенсифікації традиційних, та нових методів 
екстракорпоральної підтримки життя. Розширення областей застосування і 
збільшення накопичення досвіду і знань, створює необхідність формалізації 
знань, тобто народження технології екстракорпорального життя, як науки. 
 Ядро знань в екстракорпоральних технологій, в силу своєї подвійної природи, 
являє собою синтез декількох розділів фізичної науки, та наук про життя. Як і 
будь-яка наука на ранніх стадіях розвитку, екстракорпоральна технологія 
повторно використовує методи дослідження попередників. З цим, вона 
успадковує всі труднощі клінічних досліджень, а також привносить специфічні 
перешкоди. По-перше, це вибір еталонних або «нормальних» значень. 
Приєднання до апарату штучного кровообігу просто руйнує або змінює більшість 
механізмів гомеостазу. Таким чином, поверхневе використання знань фізіології 
людини і контрольних величин в умовах штучного кровообігу є небезпечною 
помилкою.  
 Інша проблема, характерна для всіх медичних досліджень, але набагато 
більш виражена при дослідженнях в умовах штучного кровообігу є вибір критеріїв 
оцінки результату. Признається, що кінцеві клінічні результати є найбільш надійні 
в медичних дослідженнях і є переважне мірило результатів будь-якого клінічного 
дослідження. Тим не менше, багатоетіологічниї характер післяопераційних 
ускладнень створює додаткові перешкоди досліджень, та може призвести до 
помилкових висновків. Глава 2 цього рукопису являє собою спробу «побачити ліс 
за деревами», і обійти ці перешкоди. Визначення природних груп (кластерів ) у 
популяції з 1300 випадків дозволило продемонструвати, що деякі пацієнти з 
великими коливаннями в гемодинаміки під час штучного кровообігу, мають 
підвищений ризик розвитку післяопераційних неврологічних ускладнень.  
 Незважаючи на явну перевагу кінцевих клінічних результатів, у багатьох 
дослідженнях різниця між кінцевими клінічними результатами низька, що 
призводить до необхідності великого розміру вибірки і подальшого поздовжнього 
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спостереження до отримання адекватної статистичної потужності. 
Альтернативним підходом є використання непрямих показників, таких як 
біомаркери, замість кінцевих клінічних результатів, так звані «сурогатів» клінічно 
значущих результатів. Вибір і перевірка відповідних параметрів в якості сурогатів є 
предметом численних медичних досліджень. Тим не менш, в дослідженнях в 
сфері екстракорпоральної підтримки життя, вибір сурогатних параметрів є ще 
більш складним завданням через відсутність загальновизнанних діапазонів для 
більшості параметрів кровообігу. Глава 3 цього рукопису є демонстрацією 
використання індівідуальних очікуваних значень споживання кисню 
скоректованих з урахуванням фактичного стану пацієнта в якості базової величини 
для оцінки фактичного споживання кисню. Цей індивідуальний підхід показав, що 
очевидна «залежність» середнього рівня споживання кисню від середнього 
доставку кисню це всього лише ілюзія, та що сучасні процедури штучного 
кровообігу не пов'язані з накопичення кисневого боргу. 
 Присутність штучної частини в системі апарат штучного кровообігу-пацієнт 
(“фізіологічний блок”) привносить ще більше проблем, характерних для 
екстракорпоральної технології. Вирішення цих проблем вимагає знань з фізики та 
адаптацію раніше розроблених методів дослідження в цій області. В главах 4 і 5 
наведені приклади використання методів і критеріїв «фізичної» науки для 
досліджень в екстракорпоральних технологій життєзабезпечення. Крім того, 
результати дослідження відцентрового насоса (глава 5) підкреслюють 
необхідність відповідних технологічних знань для безпечної експлуатації апарату 
штучного кровообігу (відцентрові насоси як складова частина пристрою). Питання 
про безпеку при використованні відцентрових насосів отримала подальший 
розвиток у главі 6. Винахід і впровадження в клінічну практику мініатюризації 
екстракорпоральної системи, принаймні, в деяких ситуаціях вигідно. Тим не 
менш, надмірне захоплення мініатюрними системами створює ситуацію, в якій 
небезпеки цих систем легко забуваються. У разі обмеження венозного 
повернення, кінетичний допоміжний дренаж що використовувається в цих 
системах може призвести до серйозних коливань венозного тиску в шлангу, отже, 
винекненню великі кількості газових мікроемболів. Без механізмів безпеки або 
модифікації схеми для попередження венозного повітря, газові емболи можуть 
легко проходити через мінімізовані системи штучного кровообігу, в результаті 
чого більше потенційний ризик безперервної повітряної мікроемболіі під час 
перфузії. Ми показали, що включення ємність об'ємного буфера в венозну лінію 
сприяє загасанню коливаннь нижче атмосферного тиску і зменшує навантаження 
газовими мікроемболами в експериментальних і клінічних умовах. 
 Таким чином, основна мета предмету екстракорпоральних технологій 
життєзабезпечення як міждисциплінарної науки, може бути визначена як 
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вивчення інтегральної апарат штучного кровообігу - пацієнт системи з її 
унікальними та специфічні відносинами і еталонним значеннями. Найліпшою 
практикою в управлінні екстракорпоральної підтримки життя є ретельний, баланс 
між індивідуальним вимогам пацієнта і процедурних обмежень (обмеження 
кровотоку та газообміну, розбавлення, вимоги операції, і т.д.). Ця заява містить у 
собі дві наріжних вимоги практики екстракорпоральної підтримки життя: 
• Індивідуальний підхід, який може бути сформульований як «кожен пацієнт 
унікальний, кожна процедура екстракорпорального забезпечення життя 
повинна відповідати на динамічні зміни і потреби гомеостазу пацієнта» ; 
• Перфузіолог повинен знайти підходящий баланс між вимогами пацієнта з 
одного боку та обмеженнями операції, інтенсивної терапії або реанімації, з 
іншого боку. 
 
Дуже важко передбачати, як близько намальована картина до розвитку науки, 
але що в жодному разі вкрай важливо, це щоб наріжні вимоги 
екстракорпоральної підтримки життя були ретельно збережені та передані 
майбутнім поколінням перфузіологів. 
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